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Introduction: Leukocyte- and platelet- rich fibrin (L-PRF) is a fibrin matrix in which the platelet cytokines, growth factors and cells are trapped and 
this material has been recruited in reconstruction of various defects. The aim of this study was to systematically review of the published data on the 
effectiveness of using L-PRF on regeneration of bone defects in oral and maxillofacial surgeries. Materials and Methods: Medline and Cochrane 
Central databases were searched for related articles up to and including August 2015. Being English, having ≥ four weeks follow-up, and clinical, 
radiographic, histological and histomorphometric assessments were the inclusion criteria. Results: Twenty-four animal studies and 45 human trials 
were included that reported the rate of new bone formation (NBF). Also, 38 human reports with low levels of evidence to list evaluating various 
applications of L-PRF in oral and maxillofacial reconstructions were assessed. Using L-PRF either solely or mixed in human trials was evaluated and 
divided into six groups of sinus floor augmentation and guided bone regeneration (GBR) technique, socket preservation, periodontal intra-bony 
defects (PID)  regeneration, peri-apical and endo-periodontal defects treatment, peri-implant bone regeneration and treatment of bisphosphonate-
related osteonecrosis of the jaw (BRONJ). Moreover, other uses of L-PRF with bone regeneration purposes in oral and maxillofacial surgeries were 
discussed. Conclusion: As a consequence, although L-PRF either solely or mixed showed challengeable outcomes in animal studies, it was shown to 
be effective used to accelerate and enhance new bone formation in human studies. However, future clinical trials in some treatment areas are needed 
with larger sample sizes and long follow-ups to arrive at an evidence-based conclusion.   
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Introduction 
Reconstruction of bone defects is challenging in oral and 
maxillofacial surgery (1, 2). One of the challenges facing clinical 
researchers in this field is the development of bioactive additives 
like platelet concentrates to regulate inflammation and enhance 
the healing process (3, 4). Choukroun et al., introduced 
leukocyte- and platelet- rich fibrin ( L-PRF) as a bioactive surgical 
additive to regulate inflammation and reduce the healing time 
(3). L-PRF is a new generation of platelet concentrates that is not 
only inexpensive and natural, but also does not require any 
biochemical modifications (anticoagulant, bovine thrombin or 
calcium chloride are not required) compared to other platelet 
concentrations (4-6). L-PRF is a fibrin matrix in which the 
platelet cytokines, growth factors and cells are trapped and can 
be released during a certain period of time (7). Also, it may be 
used as a resorbable membrane (8).   
According to the literature, L-PRF has been employed to 
improve the rate of bone regeneration in sinus floor 
augmentations (11), ridge augmentation and guided bone 
regeneration (GBR) (12), socket preservation (13) and treatment 
of periodontal defects (15) and endodontic lesions (15). 
Xuan et al., revealed that L-PRF membrane had a significant 
effect on new bone formation (NBF) in sinus floor augmentation 
in dogs (9). L-PRF clots reduced probing depths and gained 
significantly greater clinical attachment in periodontal defects (10). 
However, Tatullo et al., demonstrated that sinus floor 
augmentation of 60 patients using mixture of L-PRF and natural 
bovine bone mineral (NBBM) had less NBF histologically 
compared to the use of NBBM alone (11). Knapen et al., showed 
less NBF by the application of  L-PRF alone or mixed with NBBM 
in calvarial defects in rabbits compared to empty defects (12). 
Closure of alveolar clefts with symphyseal bone graft (13), closure 
of bone exposure in bisphosphonate-related osteonecrosis of the 
jaw (14), bone healing in combined endodontic periodontal lesion 
(15) and regeneration of aggressive periodontitis lesions (16) are 
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Figure 1. Flow diagram of study selection 
other applications of L-PRF reported in the literature; but 
reports are contradictory and inconclusive (24). Therefore, that 
the use of L-PRF either solely or mixed with other bone grafts 
in every oral and maxillofacial bone defects can be an effective 
approach was our hypothesis. So that, the purpose of this study 
was to systematically review the effects of L-PRF on bone 
regeneration, first in animal models which are developed for 
preclinical studies on bone regeneration, and then in various 
human oral and maxillofacial surgeries which have been 
categorized for the current study. 
Materials and Methods 
Search strategy  
This systematic review followed the Preferred Reporting Items for 
Systematic reviews and Meta-Analyses (PRISMA) statement (17). 
Electronic search for published papers up to and including August 
2015 was done in Medline (accessed through PubMed) and 
Cochrane Central databases. The following terms were searched 
alone and in combination using Boolean operators:  “platelet rich 
fibrin”, “bone”, “bone substitute material”, “bone transplantation”, 
“bone regeneration”, “bone augmentation”, “periodontal defect”, 
“apical lesion”, and “maxillofacial surgery” (Figure. 1). Online 
studies which were published electronically were also considered 
in case of accordance to our criteria of this study. Besides, we have 
manually searched the below listed journals: Oral Surgery, Oral 
Medicine, Oral Pathology, Oral Radiology, and Endodontology, 
Journal of Oral and Maxillofacial Surgery, The International 
Journal of Oral & Maxillofacial Implants, Journal of 
Periodontology and Journal of Clinical Periodontology. 
Study selection 
Bone defects in which L-PRF was used as a membrane or clot for 
reconstruction, were considered as the test group. Bone defects in 
which bone graft or bone substitute materials without L-PRF were 
used were considered as the positive controls, and defects that 
were left empty were considered as the negative controls. The 
inclusion criteria were: 1) English papers 2) follow-up period of 
four weeks or more and 3) reporting clinical, radiographic and 
histological findings. Authors had tried to do not miss any 
papers of using L-PRF regarding bone regeneration purposes 
related to inclusion criteria. Also, studies with few cases were 
included as studies with low level of evidence.  
Data extraction 
A data extraction form was designed to collect data on the type 
of materials used, membranes, number of patients and samples, 
data evaluation methods, the follow-up periods, and the 
outcomes. Descriptive results of selected studies were extracted 
and collected in tables separately according to the technique 
applied for using L-PRF in surgeries with different indications 
for bone regeneration. 
Results 
Animal trials 
Table 1 shows 24 studies conducted on rats (18-20), rabbits (12, 
21-32), dogs (9, 33-36) , pigs (37, 38) and sheep (39). Defects 
were created in calvarium in 12 studies (12, 18-25, 27, 29, 31), in 
the tibia in four (26, 28, 37, 39), in the sinus in two (9, 34), in 
dental sockets in two (33, 38), in femur in two (32, 35), in 
mandible in one (30) and as an alveolar cleft in one study (36). 
The sacrificing times had started from one week (22) and 
finished to six months (9, 36) post-operatively. In 15 studies, L-
PRF was used as a mixture with tricalcium phosphate (TCP) (27, 
37), biphasic calcium phosphate (BCP) (32, 39),  hydroxyapatite 
(31), NBBM (12, 20, 22), autologous bone graft (ABG) (36), 
deproteinized bovine bone (DBB) (23), tooth ash (TA) (35), silk 
fibroin powder (SFP) (28, 29), bone marrow stromal cells 
(BMSCs) (19, 36), and epithelialized palatal free graft (FGG) as 
an autologous membrane (38). In six studies, L-PRF was used as 
a sole grafting material (21, 25, 26, 30, 33, 34). One study used L-
PRF membrane in conjunction with titanium barriers for GBR 
(25). Furthermore, one study compared L-PRF membrane with a 
commercial one (9). With regard to the preparation methods, 
Tunali et al., evaluated titanium-prepared PRF (T-PRF) 
membranes prepared in titanium tubes in comparison with 
Chouckroun’s preparation method in glass tubes (24) (Table 1). 
In terms of storage of L-PRF, Li et al., compared lyophilized PRF 
with fresh PRF for use in calvarium defects in rats (18) (Table 1).  
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In 18 studies, the rate of NBF was reported mainly based on 
histomorphometric analysis (HA), while others performed 
histological (24) and stereology assessments (37), micro 
computed-tomography (CT) scans (19, 33) and quantitative CT 
(qCT) (32, 36) based  on bone mineral density measurement 
(Hunsfield unit). According to HA, the lowest percentage of 
NBF was observed in L-PRF mixed with NBBM and reported to 
be 5.00 ±3.74% after one week in calvarial defects of rabbit model 
(22), whereas the highest percentage was 87.5±9.15%  and 
observed after eight weeks in peri-implant bone defects created 
in the femur of dog model receiving a mixture of L-PRF and 
tooth ash powder (35). Moreover, when L-PRF clots were used as 
the sole grafting materials, the lowest percentage of NBF was 
demonstrated to be 7.4±0.7% after 10 days in tibial defects of 
sheep (39) , while the highest rate was 50.70±4.60% and observed 
after 12 weeks in calvarial defects of rabbits (21). According to 
qCT analysis, while subcortical and cortical area of defects 
treated with L-PRF alone was significantly more when compared 
to using mixture of L-PRF and BCP three months 
postoperatively, subcortical and cortical density of L-PRF sole 
grafting which were measured 982.66 ± 61.78 and 1028.27 ± 
44.12 , respectively, showed non-significant difference (32).  
Human trials  
Maxillary sinus floor augmentation and GBR technique  
Thirteen studies were aimed at evaluating the rate of bone 
regeneration in sinus floor augmentation (8, 11, 40-50) 
(Table 2). Follow-up appointments were between 106 days 
(11) and 1 year (47). HA was used in eight studies (11, 40, 
42, 46, 48-51), while the evaluation methods of the other 
ones were both clinical and radiological (43-45, 47) or CT 
scan evaluations (41). Five studies used L-PRF clots mixed 
with NBBM (11, 42, 45), deproteinized bovine bone mineral 
(DBBM) (50) and FDBA(48). Five studies used L-PRF in 
sinus lift surgeries as the sole graft material (41, 43, 44, 46, 
47), two of which used it with osteotome-mediated sinus 
floor elevation (OMSFE) technique (44, 47). Also, L-PRF 
membrane was compared with collagen membrane in three 
studies (8, 40, 49). 
NBF of L-PRF was reported to be 33±5% after six months 
used as the sole graft material (46), but  37.06%  after 150 days 
or 18.35%±5.62% after six months when mixed with NBBM 
(11, 42), 34.5 ± 5.7% after 7-10 months mixed with DBBM and 
31.24% after four months mixed with FDBA (48).  NBF by 
using L-PRF membrane varied from 17.0 (7.8-27.8)% after five 
months (8), 35.0±8.60% after six months (49) and  28.6±6.90% 
after seven to 11 months (40). There were no statistically 
significant differences between them and control groups; 
furthermore, the rate of residual graft material (RGM) was not 
significant between the two groups.  
After sinus floor augmentation, dental implants were 
inserted immediately in six studies (41, 43-47, 52), but in the 
other seven studies it was performed in second surgeries (8, 11, 
40, 42, 48, 50). Nine studies reported survival rates of inserted 
dental implants about  97.1% (47), 97.8% (44) and 100% (40, 41, 
43, 45, 46, 49, 51)  at least after 12 weeks (40) up to 6 years (43) 
postoperatively.   
Eleven articles reported GBR techniques (53-58), sinus floor 
augmentation (52, 59, 60), 3-D augmentation of alveolar ridge 
using titanium mesh and bone morselizer (61) and vertical 
alveolar distraction technique (62) with low level of evidence 
(Table 3). For instance, a new minimally invasive GBR was 
reported for using L-PRF mixed with bone substitute materials 
in 11 patients and showed 2.4 to 5.1 mm vertical and 1.3 to 3.9 
mm horizontal gain (57).    
Socket preservation 
Eleven studies evaluated the effectiveness of L-PRF on socket 
preservation (63-71) (Table 4); two of them had low level of 
evidence (67, 71) (Table 5). Socket preservation was performed 
in molar sites (66, 68-70, 72, 73), non-molar sites (64, 65, 69), 
and buccal bone plate dehiscence of the anterior maxilla (63). 
Methods of evaluation were clinical and radiographic (63, 65, 68-
70, 73), serial radiovisiography (RVG) (66), technetium-99m 
methylene diphosphonate uptake(72) and both micro CT scans 
and histology (64). L-PRF was used as a sole graft material in 
eight articles in which the results of L-PRF group were not 
significantly better than controls (64-66, 68-70, 72, 73) (Table 4). 
According to a prospective randomized controlled study, even 
though a significant effect on intrinsic bone quality was 
observed, bone volume/ total volume (BV/TV) ratio gathered 
from micro-CT scans after eight weeks in L-PRF group was not 
significantly greater than L-PRF with mucosal flap or sham 
group (64).  When L-PRF was mixed with corticocancellous 
porcine bone (CCPB) and collagen membrane (74), bone level 
significantly improved after five months in the distal sites (63)  
(Table 4).    
Periodontal intra-bony defects regeneration  
Seventeen studies were found regarding regeneration of 
periodontal intra bony defects (PID) (10, 75-87), horizontal 
defects(88) and grade II mandibular furcation involvement (89, 
90) (Table 5). L-PRF was applied alone (10, 76, 78, 79, 82, 85-90) 
or mixed with DFDBA (77, 81), bovine porous bone mineral 
(BPBM) (75), nanocrystalline hydroxyapatite (NcHA)(83), 
bioactive glass (BG) (91) and 1% metformin (92). Follow-up 
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appointments were six months (75, 77, 83, 85-87, 91), nine months 
(76, 78, 79, 82, 88-90, 92), and one year (10, 81). Probing depth 
reduction (PDR), clinical attachment gain (CAG), radiologic bone 
fill (RBF) and defect depth reduction (DDR) were investigated. In 
12 studies, the parameters significantly improved in follow-ups 
than base-line evaluations (10, 77, 81-83, 85-90, 92). Both PDR 
and CAG were significantly greater in case than in control groups 
in nine studies (10, 75, 77, 79, 81, 88-90, 92). In three studies, sole 
use of L-PRF was compared to using ABG(85), DFDBA(86) and 
enamel matrix derivatives (EMD) (87) in which both PDR and 
CAG were not significant between the understudy groups.  All 
studies in which the RBF was evaluated showed a significant filling 
of defects radiographically using L-PRF compared to control 
groups (75, 76, 78, 79, 81, 89, 90, 92). DDR, also had significant 
enhancement in the L-PRF group (Table 5) (10).  
Moreover, four studies with low level of evidence 
investigated the application of L-PRF according to the 
treatment of labial-cervical-vertical groove (LCVG) (93), 
generalized aggressive periodontitis (GAgP) (16) and intra-
bony defects (Table 6) (94, 95).  
Peri-apical and endo-periodontal defects treatment  
Two clinical trials were conducted on using L-PRF as a sole 
material to manage periapical lesions and apico-marginal defects 
(Table 7) (96, 97). Singh et al., reported complete bone 
regeneration of periapical lesions after six months (96). Also, 
Dhiman et al., showed significant PDR but not CAG using sole 
L-PRF in treatment of apico-marginal defects after one year (97).  
Fourteen studies reported some cases in which L-PRF was 
used for treatment of endodontic-periodontal lesions (15, 98-
103), apical lesions (104, 105) and radicular cysts (106-110) with 
a low level of evidence (Table 8). For this purpose, L-PRF was 
used as the sole material (100, 102-104, 108), or mixed with iliac 
bone graft (110), hydroxyapatite (105), DFDBA (106), BG (15, 
107) or β-TCP (109). 
Peri-implant bone regeneration   
Three randomized clinical trial used L-PRF alone in treatment of 
peri-implant bone defects (111), prevention of bone loss after 
dental implant insertion (112) and increasing stability of inserted 
dental implants in a drilled hole filled with L-PRF (Table 9) 
(113). One study reported healing of retrograde peri-implantitis 
using a mixture of a xenograft with L-PRF(114). Another study 
used L-PRF in immediate implant insertion after extraction of a 
fractured central incisor (Table 9) (115). 
Treatment of bisphosphonate-related osteonecrosis of the 
jaw (BRONJ) 
Three studies were found on the effect of L-PRF on the treatment 
of bisphosphonate-related osteonecrosis of the jaw (BRONJ) (14, 
115-117) (Table 10). Two studies used L-PRF clot (116) and 
membrane(14) alone, and another study mixed with recombinant 
human bone morphogenetic protein 2 (rh-BMP2) (117).  
Other uses of L-PRF for bone regeneration 
According to bone regeneration purposes, three other studies 
were found. L-PRF mixed with DFDBA was used in a novel 
technique of ridge augmentation with long palatal connective 
tissue rolled pedicle graft (118)  and auto-transplantation of an 
impacted central incisor (Table 11) (119). Moreover, a mixture 
of L-PRF and autogenous symphyseal graft was used in alveolar 
cleft treatment (13). 
Discussion 
Recently, applications of L-PRF have been presented in various 
studies for different purposes like regeneration of both hard and soft 
tissues (74), dental pulp revitalization (120) , tooth root regeneration 
(121), wound healing (122), treatment of articular cartilage defects 
(123), rejuvenating media for avulsed teeth (124), chronic lower-
extremity ulcers (125), etc. The present study was a systematic 
review designed to appraise the available evidences regarding the 
effectiveness of L-PRF on regeneration of different bone defects in 
oral and maxillofacial surgeries. In this study, the effectiveness of L-
PRF was discussed at first in animal models, then, was categorized 
and discussed in treatment of six different human bone defects 
according to the various surgeries and techniques finally the results 
of three studies with other bone defects and techniques were 
reviewed. Although Shah et al., (126)  have recently systematically 
reviewed the effect of sole L-PRF on periodontal intra bony defects, 
the current study has systematically reviewed the studies in which L-
PRF was used either sole (n=12) or in combination with other bone 
grafts (n=5) in periodontal defects, in addition to six recent 
published clinical studies in 2015. Furthermore, we have discussed 
the results of a recent systematic review on application of L-PRF in 
sinus floor augmentation by Sherif et al., (127) although due to the 
main aim of our study, the data were extracted differently and the 
results of five other clinical studies were also  considered. However, 
due to co-application of L-PRF with various bone grafts and various 
quality of included studies, it was not feasible to meta-analyze the 
included studies.  
Using L-PRF in animal models  
Fourteen studies evaluated the L-PRF mixed with different bone 
grafts, but eight studies were conducted on using L-PRF alone. 
Among studies which evaluated mixtures of L-PRF, 12 indicated 
significant effect of adding L-PRF to ABG (23, 36), SFP (28, 29), 
TCP (27), NBBM (9, 20), TA (35), BCP (31, 32, 39) and BMSCs (19, 
36), while, in the other studies, mixtures of L-PRF with TCP (37)  
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Table 1. Included animal studies, which used PRF in bone regeneration 
 
Number and type 
of animals 
Defect location 
& size 
Used materials  
Evaluatio
n 
methods  
Bone gain  
Pripatnanont 
et al. (30)  
12, rabbit 
Periosteal 
distraction 
(mandible) 
Hyrax device (A) 
Hyrax device + L-
PRF (B)  
HA 
Micro-CT 
NBF 
After 4 weeks: A: 23.21 ± 11.00%, B: 41.37 ± 7.57%* 
After 8 weeks: A: 33.25 ± 5.46%, B: 55.46 ± 10.67%* 
Yuanzheng et 
al. (36) 
20, dog 
Unilateral 
alveolar cleft 
ABG + BMSCs+ 
L-PRF (A) 
ABG+BMSCs(B) 
ABG+L-PRF (C) 
ABG (D) 
Quantitati
ve CT 
Histologic 
 
Graft resorption after 6 mo.: 
A* vs. B,C,D 
B* vs. D & C* vs. D    
HA does not performed to report the NBF rate 
Oliviera et al. 
(20) 
48 rats cranium, 5mm 
Bio-Oss®   
L-PRF 
Comb. 
HA 
NBF  
After 30 days: L-PRF: 21.77% 
Bio-Oss®: 26.15%  Comb.: 54.05%* 
After 60 days: L-PRF: 23.03%  
Bio-Oss®: 57.34%*  Comb.: 63.58%* 
Acar et al. 
(31) 
20 rabbits 
Calvarium, 
6mm 
HAp/BCP  
L-PRF 
Comb. 
HA 
Micro-CT 
NBF  
After 4 weeks: L-PRF: 13.86±5.26%, HAp/BCP: 14.81±4.72%  
, Comb.: 27.40±7.33%*  
After 8 weeks:  L-PRF: 24.51±7.71%**, HAp/BCP: 
24,50±3,87%**,  
Comb.: 39,10±8,10%*,**  
Nacopoulos 
et al. (32) 
15 rabbits 
Femoral 
condyle  
L-PRF 
L-PRF+BCP 
Histologic 
Quantitati
ve CT 
After 3 mo.: 
Bone density : L-PRF+BCP* vs. L-PRF 
Cortical and subcortical areas:  L-PRF+BCP* vs. L-PRF 
Yilmaz et al. 
(37) 
3 pigs Tibia, 5mm 
β-TCP  
L-PRF 
Comb. 
Stereology   
NBF after 12 weeks:   
β-TCP: 21.1 ±2.8µm2* 
L-PRF: 18.2 ±5.1 µm2*,  
β-TCP +PRF: 22.1±7.4 µm2* 
Kim et al. 
(21) 
12 rabbits 
Calvarium, oval 
10mm+15mm 
PRP  
L-PRF  
CGF 
HA 
NBF: 
After 6 weeks: PRP: 36.86±4.86%* ,  
L-PRF: 37.85±3.40%*, CGF: 39.18±2.46%* 
After 12 weeks: PRP:52.69±2.16% ,  
L-PRF: 50.70±4.60%, CGF:57.52±2.48% 
Li et al. (18)  A rat  Cranium CSBD   
LPRF 
L-PRF:  
Fibrin gel 
HA 
After 6 weeks*: LPRF: 62.13±1.89%*, 
L-PRF: 43.91±1.35%*,  
Fibrin gel: 31.65±5.84%* 
Yoon et al. 
(22) 
10 rabbits Calvarium 7mm 
Bio-Oss®+ L-PRF 
Bio-Oss® 
HA 
NBF at 1st week: test: 5.00 ±3.74  control: 6.50±3.11 NS   
at 2nd week: test:  30.00±10.00  control: 40.00±10.00 NS 
at 4th week: test: 63.33±23.09  control: 51.67±12.58 NS 
Xuan (9) 6 dogs Sinus,- 
Bio-Oss®+ Tisseel® 
Bio-Oss®+ L-PRF 
HA 
After 6 mo.:  
NBF:  L-PRF: 41.8±5.9%*, Tisseel®: 31.3±6.4%  
OR:  L-PRF: 43.5 ± 12.4% *,  
Tisseel®: 30.7 ± 7.9% 
Srisurang et 
al. (38) 
6 minipigs,  Dental socket,- 
L-PRF 
FGG (control) 
Comb.  
HA 
OD 
After 12 weeks: NBF was higher in PRF than others. NS 
OD in  L-PRF: 158.57±30.74*,  FGG:108.59±29.99, Comb.: 
111.69±21.36 & empty: 91.31±37.33 
Hatakeyama 
et al. (33) 
12 dogs  Dental socket,- 
PPP 
PRP 
L-PRF 
Micro-CT 
Median area of NBF at 4th week (mm2): PPP: 5.85*, PRP: 3.66, 
L-PRF: 5.22* & control: 3.55. At 8th week: PPP: 7.52*,  PRP: 
4.50,  L-PRF: 5.98 & control: 5.93 
Jeong S. et al. 
(34) 
6 dogs 
Sinus 1+ 
1.5 cm2 
L-PRF 
HA 
CT scan 
The height of NBF around the implants in the sinus after 6 
mo.: Buccal side:2.6±2.0 mm & 
Palatal side:1.3±1.8 mm  
Pripatnanont 
et al. (23) 
10 rabbits  
Calvarium 
10+10 mm 
ABG (A) 
DBB (B) 
L-PRF (C) 
ABG+DBB (D) 
ABG+ L-PRF (E) 
DBB+ L-PRF (F) 
ABG+ DBB +PRF 
(G) 
HA 
NBF after 8 weeks:  E: 38.03 ± 4.23%* was significantly higher 
from F: 13.067 ± 3.64%* & G: 22.63 ± 3.6%* and  C: 
18.81 ± 9.27%* 
And D: 21.29 ± 3.52% was significantly higher than B:  
9.63 ± 5.47% 
Tunali et al. 
(24) 
6 rabbits  Calvarium 7mm T-PRF 
Histology 
 
 NBF were noted on the 15th day, 3 aspects on 30th day: 
inflammation (remaining membrane), granulation tissue & 
remodeling areas.  
Knapen et al. 
(12) 
18 rabbits  Calvarium 8mm 
L-PRF 
Bio-Oss® 
Comb. 
HA 
NBF after 12 weeks:  L-PRF: 24.11±6.57%**, Bio-Oss®: 
21.15±7.24%**, Comb.: 21.42±7.37%** 
 Empty: 25.77± 8.41%** 
Honda et al. 
(19) 
27 rat 
Calvarium 
CSBD 
L-PRF 
L-PRF+ BMSCs 
Micro-CT 
NBF in all the times:   L-PRF+BMSCs*>  L-PRF > empty               
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Bolukbasi et 
al. (39) 
6 sheep  Tibia 5mm 
BCP 
L-PRF 
Comb. 
HA 
NBF in Comb. after 10days:11.4±0.7*,  
20days: 42.2±0.9* & 40days: 54.9±0.8* was significantly higher 
than BCP and L-PRF groups in that times. 
Jeong K. et 
al. (35) 
6 dogs 
Femur (around 
implants), 8mm 
TA (A) 
TA+ L-PRP (B) 
TA+PRF (C) 
HA 
NBF at 4th week (%): A: 57.9±22.79  B: 52.8±26.85, C: 
78_8±6.95*,  control: 38.3±15.84 
NBF at 8th week (%): A: 70.8±11.11, 
B: 65.8±27.03, C: 87.5±9.15*,  control: 59.5±9.24 
Ozdemir et 
al. (25) 
24 rabbits  Calvarium ,- 
L-PRF 
Bio-Oss® 
4BoneTM 
HA 
after 3 month, NBF in test : was significantly higher than 1 
month & control group 
NBF at both times:  L-PRF> Bio-Oss®>4BoneTM NS 
Lee et al. (26) 8 rabbits 
Tibia 
width:3.0mm, 
length:5.0mm 
L-PRF HA 
After  8 weeks NBF in  L-PRF:29.30%±7.50%* 
& in control :11.06%±8.94% 
Kim et al. 
(27) 
36 rabbits   
Calvarium , 
8mm 
TCP+rhBMP2(A) 
TCP+ L-PRF (B) 
TCP (C) 
HA 
NBF at 2nd week: A: 4.8%, B: 11.4%*,  C: 0% 
At 4th week: A: 22.3%, B: 27.3%*, C: 17.1%  
At 6th week: A: 28.0%, B: 37.4%*, C: 19.6% 
At 8th week: A: 30.3%, B: 41.5%*,  C: 29.9%  
Jang et al. 
(28) 
10 rabbits  
Tibia (around 
implants), 7mm 
SFP+ L-PRF HA 
After  8 weeks NBF in test: 51.93 ± 27.90%* 
& in control : 11.67 ± 15.12% 
BIC in test: 43.07. 21.96%* & in control: 15.37. 23.84% 
Lee et al. (29) 10 rabbits 
Calvarium , 
9mm 
SFP+ L-PRF HA 
After 6 weeks NBF in test: 44.38 ± 17.00% & control: 36.59 ± 
6.11 NS 
& after 12 weeks : 59.83 ± 10.92%*  
In control: 49.86 ± 7.49% 
CT: Clinical trial, CR: Case report, RS: Retrospective study, RSMD: randomized split-mouth design, CS: Case series, NR: Not reported, HA: 
Histomorphometric analysis, NBF: new bone formation, NS: not significant, RGM: residual graft material, DBBM: deproteinized bovine bone mineral, ABG: 
autologous bone graft, CT scan: computed tomographic scan, HU: Hounsfield units, L-PRF: Leukocyte- and platelet-rich fibrin, BBG: Bovine bone graft, 
RCM: Resorbable collagen membrane, OMSFE: osteotome-mediated sinus floor elevation, BAOSFE: bone-added osteotome sinus floor elevation 
Table 2. Included human studies using PRF in sinus floor augmentation 
 Type of 
study 
Number of 
patients, 
sites, 
implants  
Type of 
surgery 
Used materials Evaluation 
methods 
Bone gain Survival 
rate of 
implants 
(follow-up 
point) 
Tanaka et 
al. (50) 
Prelimina
ry study 
4,4,- Two 
stage 
DBBM/L-PRF HA After 7-10 mo.: 
34.5 ± 5.7% 
- 
Bosshardt 
et al. (40) 
CT 12, 16, 16 Two 
stage 
NanoBone + L-PRF 
NanoBone +RCM 
HA  After 7-11 mo.:  
NBF in  L-PRF (%): 28.6±6.90 
RCM: 28.7±5.4 NS 
RGM in  L-PRF (%): 25.7±8.8 
RCM: 25.5±7.6 NS 
100%, 12 
weeks 
Gassling 
et al. (8) 
RSMD 6, 12 , 32 Two 
stage 
Bio-Oss® +ABG+  
L-PRF 
Bio-Oss® +ABG+ 
RCM 
HA After 5 mo. NBF in  L-
PRF:17.0 (7.8-27.8)% &  RCM 
: 17.2 (8.5-24.2) % NS 
RGM in  L-PRF(%): 15.9 (0.9-
33.4)% & in  RCM: 17.3 (0.7-
33.5)% NS 
100%,12 
mo. 
Tajima et 
al. (41) 
CS 6, 9, 17 One 
stage 
L-PRF (sole 
material) 
CT scan After 6 mo., the mean density 
of NBF around the implants : 
323 ± 156.2 HU (185 to 713 
HU) 
100% , 6 
mo. 
Bölükbaşı 
et al. (49) 
RS 25,32,66 Two 
stage 
Bio-Oss®+ L-PRF 
BioOss®+RCM 
HA After 6 mo.:  
NBF in PRF (%):35.0±8.60 
RCM: 32.97±9.71 NS 
RGM in  L-PRF (%): 
33.05±6.29, RCM:  33.79±8.57  
NS 
100%, 30 
mo. 
Tatullo et 
al. (11) 
CS 60, 72, 240 Two 
stage 
Bio-Oss®+ L-PRF 
Bio-Oss® 
Histologic & 
clinical 
Trabecular bone after 106 
days in test : 22.79% & in 
control: 26.44% NS 
after 120days in test: 26.15% 
in control: 28.7% NS 
ater 150 days in test: 37.06% 
in control:38.97 NS 
NR 
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Zhang et 
al. (42) 
CS 10, 11, NR Two 
stage 
Bio-Oss®+ L-PRF 
Bio-Oss® 
HA After 6 mo., NBF in  L-PRF 
vs. control: 18.35%±5.62% vs. 
12.95%±5.33% NS 
RGM: 19.16%±6.89% vs. 
28.54%±12.01%  NS 
NR 
Simonpie
ri et al. 
(43) 
CS 20, 23, 32 One 
stage 
L-PRF (sole 
material) 
Radiographi
c &clinical  
After 6 mo., vertical bone gain 
was 10.4 ± 1.2 (range, 8.5 to 
12 mm) & periimplant crestal 
bone height was stable. 
100%, 6 year 
Toffler et 
al. (44) 
CS 110,138,138 One 
stage 
L-PRF (sole 
material) 
Radiographi
c &clinical 
The mean increase in the 
height of implant sites by 
OMSFE/PRF was 3.4 mm 
(range, 2.5 to 5 mm). 
97.8% 
Inchingol
o et al. 
(45) 
CS 23,31,95 One 
stage 
  
Bio-Oss®+ L-PRF 
 
Radiographi
c &clinical 
presence of an optimal PS of 
inserted implants & 
significant increase in the 
peri-implant bone density 
100%, 6-9 
mo. 
Mazor 
(46) 
CS 20,25,41 One 
stage 
L-PRF(sole 
material) 
Radiographi
c  & HA 
After 6 mo. all biopsies 
showed well organized and 
vital bone, NBF: 33±5%. 
100%, 6 mo. 
Diss et al. 
(47) 
CS 20,-,35 One 
stage 
L-PRF/ BAOSFE Radiographi
c 
The mean endosinus gain:  
mesial side: 3.5 ± 1.4 mm 
(max: 5.8, min:0.9) &   
distal side: 2.9 ± 1.6 mm 
(max:5.2, min:0.1)  
97.1%, 1year 
Choukrou
n et al. 
(48) 
CS NR, 9, NR Two 
stage 
FDBA+L-PRF 
FDBA 
HA Trabecular bone after 4 mo. 
in test: 31.24% & after 8 mo. 
in control: 30.36%   
NR 
L-PRF: Leukocyte- and platelet-rich fibrin, PeSPTT: Piezotome enhanced subperiosteal tunnel technique, GBR: Guided-bone regeneration, OMSFE: 
osteotome-mediated sinus floor elevation, VAD: Vertical alveolar distraction , NR: Not reported, PLGA: polylactic-co-glycolic acid, BCP: Biphasic calcium 
phosphate, TCP: Tricalcium phosphate, ABG: Aoutogenous bone graft, BHA: Bone hydroxyapatite, ASG: autogenous symphseal graft, CBCT: cone-beam 
computed tomography scan, BSM: Bone substitute material  
Table 3. Included studies using L-PRF in GBR technique and bone augmentation 
 
Number of 
cases  
Used material  Technique 
Evaluation 
method 
Bone gain 
Survival rate of implants 
(follow-up point) 
Angelo et 
al. (58) 
82  
PLGA coated BCP 
PLGA coated TCP 
PLGA coated TCP+ L-
PRF 
PeSPTT 
Clinical 
(insertion 
torque value) 
CBCT 
Superior biomechanical 
stability in  PLGA coated 
TCP alone or combined 
with L-PRF 
 
Zhao et 
al. (60) 
One L-PRF Two stage sinus lift 
Clinical, 
radiographic & 
histologic 
NBF observation and 
dental implants insertion 
after 6 months 
 
Toffler et 
al. (53) 
Two L-PRF membranes 
GBR + Allogeneic 
cortical bone pins (2 
mm in diameter in 
customized lengths) 
CBCT 
Provide both horizontal 
&vertical ridge 
augmentation at severely 
compromised implant 
sites 
NR 
Kanaya
ma et al. 
(52) 
Two L-PRF (sole material) 
One stage sinus 
augmentation & 
implantation 
CT scan 
HU valu at final follow-
up was increased in case 
1 to 1240 (corresponding 
to cortical 
Bone) & in case 2 to 675  
(corresponding to 
porous cortical and fine 
trabecular bone) 
100% ,12mo. 
Montana
ri et al. 
(54) 
One L-PRF+ ABG+ BHA 
GBR with 5 PRF 
membrane 
CBCT 
A predictable method of 
augmenting deficient 
alveolar ridges after 4 
mo. 
NR 
Gowda et 
al. (61) 
One ASG+L-PRF 
3-D augmentation of 
alveolar ridge using 
Clinical  
An increase in a ridge 
width of 2 mm and 
NR 
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titanium mesh and 
bone morselizer 
height by 4-5mm after 4 
mo.  
Kim et 
al. (55) 
Two L-PRF + BioCera® 
GBR+ Double J 
technique 
Histology 
After 16 weeks: Presence 
of a substantial amount 
of osteoid tissues & vital 
bone, & infiltration of 
new bone to the grafted 
materials. 
Good esthetic 
&functional results after 
6 mo. & 1year in both 
cases.    
100%, 1year  
Gupta et 
al. (67) 
One L-PRF+ BCP 
Compromised 
extraction sockets 
preservation 
Clinical &  
radiographic 
satisfactory and 
successful regeneration 
after 6 mo. 
 
Vijayalak
shmi et 
al. (56) 
One 
L-PRF+ BG+ 
resorbable membrane 
GBR (fenestration 
around an implant) 
Clinical 
After 6 mo, buccolingual 
width of the ridge was 7 
mm.  
NR 
Peck et 
al. (59) 
Two L-PRF OMSFE 
Clinical &  
radiographic   
No pain or movement of 
implants was reported & 
NBF was observed 
No report 
Kocyigit 
et al. (62) 
One 
ASG+ 
L-PRF (at first step) 
VAD to maintain the 
suitable bony height 3 
months after first step 
Clinical &  
radiographic   
A total of 11 mm vertical 
height was gained with 
VAD & Sufficient bone 
volume and height were 
observed after 12-month 
follow-up period 
NR 
Peck et 
al. (59) 
Two L-PRF 
Compromised 
extraction sockets 
preservation 
OMSFE 
Clinical &  
radiographic 
Successful alveolar ridge 
preservation & sinus 
floor augmentation  
 
Peck et 
al. (71) 
One L-PRF 
Compromised 
extraction sockets 
preservation 
Clinical &  
radiographic 
Successful implant 
placement 6 weeks after 
tooth extraction 
 
Kfir et 
al. (57) 
11 BSM+L-PRF 
A new minimally 
invasive GBR 
CT scan, 5 to 6 
mo. 
vertical gain: 2.4 to 5.1 
mm & horizontal gain: 
1.3 to 3.9 mm.  
NR 
L-PRF: Leukocyte- and platelet-rich fibrin, PeSPTT: Piezotome enhanced subperiosteal tunnel technique, GBR: Guided-bone regeneration, 
OMSFE: osteotome-mediated sinus floor elevation, VAD: Vertical alveolar distraction , NR: Not reported, PLGA: polylactic-co-glycolic acid, BCP: 
Biphasic calcium phosphate, TCP: Tricalcium phosphate, ABG: Aoutogenous bone graft, BHA: Bone hydroxyapatite, ASG: autogenous symphseal 
graft, CBCT: cone-beam computed tomography scan, BSM: Bone substitute material 
Table 4. Included studies using L-PRF in socket preservation 
 
Type of 
study 
Number of 
patients & 
involved 
location 
Used materials  
Evaluation 
methods 
Bone gain 
Baslarli et 
al. (72) 
CT & SMD 20, 40 3rd MMs L-PRF 
technetium-
99m 
methylene 
diphosphonate 
uptake 
No significant different between PRF-treated and non-PRF-
treated sockets after 30 and 90 days postoperatively 
Kumar et al. 
(73) 
RCT 31,31 3rd MMs L-PRF 
Clinical & 
radiographic 
After 3 mo.: 
Significantly mean pocket depth reduction after 1 and 3 
months in both test and control groups 
Increased radiographic factors non-significantly in L-PRF 
group   
 
Barone et al. 
(63) 
CS 
33, anterior of 
maxilla, BBD 
CCPB+  
L-PRF+ CM 
Radiographic  
Improvement of vertical bone level after 5 months: 
0.8 ± 0.1 mm (mesial site)* 0.7 ± 0.1 mm (distal site)* 
Hauser et al. 
(64) 
RCT 
23, premolar 
site 
L-PRF  
L-PRF+ mucosal 
flap 
Micro-CT & 
histologic  
BV/TV after 8 weeks: PRF: 0.281±0.037, PRF+ flap: 
0.197±0.027, control: 0.249±0.037 
A significant effect on intrinsic bone quality &  
preservation of the alveolar width was observed using PRF vs. 
L-PRF+ flap 
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Srisurang et 
al. (65) 
CT & SMD 
10, 20 premolar 
sites 
L-PRF Clinical  
First week: HR on buccal aspect of PRF (1.07 ± 0.31 mm) 
control (1.81 ± 0.88 mm)* 
PRF had faster bone healing than control: NS 
Girish Rao 
et al. (66) 
CT 22, 44 3rd MMs  L-PRF  
Serial RVG at 
0 & 1 day & 1,3 
& 6 m. 
The mean pixels recorded between test and control groups: NS 
Singh et al. 
(68) 
CT 20, 40 3rd MMs L-PRF 
Clinical & 
radiographic  
After 12 weeks: TBF was seen in all of both groups  
GSV for L-PRF: 146.9* and for control: 123 
Simon et al. 
(69) 
CT 
21, 6 molar&15 
premolar sites  
L-PRF 
Clinical & 
radiographic 
After 4 months: Mean WR for L-PRF (mm): 0.32 (4.71%) & 
control: 0.57 (7.38%): NS 
Ruga et al. 
(70) 
CT NR, 28 3rd MMs L-PRF Clinical  
After 6 months: Sufficient and adequate socket fulfillment 
In all L-PRF cases   
PDR in L-PRF: 0.86mm & control: 0.5 mm NS  
CS: Cohort study, CT: Clinical trial, RCT: Randomized controlled trial, SMD: split mouth design, NR: Not reported, BBD: buccal bone plate 
dehiscence, L-PRF: Leukocyte- and platelet-rich fibrin, CM: Collagen membrane, CCPB: Corticocancellous porcine bone, HA: 
Histomorphometric analysis, HR: horizontal resorption, WR: width resorption, *significant difference regarding base line, NS: Not significant, 
MMs: Mandibular molars, RVG: radiovisiography, TBF: trabecular bone formation, PCT: periodontally compromised tooth , GSV: gray scale 
value, PDR: probing depth reduction 
 
Table 5. Included studies using L-PRF in periodontal intra bony defect regeneration 
 
Type of 
Study 
Number of cases, 
problem 
Used materials 
Evaluation 
method 
Bone gain 
Agrawal  et al. 
(81) 
SMD 60,  PID with CP 
L-PRF+ DFDBA (A) 
DFDBA(B)  
Clinical & 
radiographic 
After 12 months**: 
PDR in  A (mm): 4.15 ± 0.84* &  
B: 3.60 ± 0.51 
CAG in  A (mm): 3.73 ± 0.74* &  
B: 2.61 ± 0.68 
Defect fill in  A (mm): 3.50 ± 0.67* &  B:2.49 ± 0.64  
Ajwani  et al. 
(82) 
SMD 40,  PID 
L-PRF+OFD 
OFD 
Clinical & 
radiographic 
After 9 months**: 
Mean PDR in  L-PRF vs. control: 1.90mm vs. 1.60mm 
Mean CAG in  L-PRF vs. control: 1.80mm vs. 2mm 
Elgendy & 
Shady 
(2015)(83) 
SMD 40, PID 
L-PRF+ NcHA 
NcHA 
Clinical & 
radiographic 
After 6 months**: 
Mean PDR in  L-PRF+ NcHA: 3.33mm & NcHA: 
3.30mm 
Mean CAG in  L-PRF+ NcHA vs. & NcHA: 3.55mm vs. 
3.50mm  
Mean RBD changes: L-PRF+ NcHA* vs. NcHA: 34.45 vs. 
16.86 
Pradeep  et al. 
(92) 
RCT 120,  PID with CP 
1%MF+L-PRF+OFD 
(A) 
1%MF+OFD (B) 
L-PRF+OFD (C) 
OFD (D) 
Clinical & 
radiographic 
After 9 months**: 
PDR in A (mm):4.90±0.30*, B:3.93±0.25*, C:4.00±0.18* 
& D:3.00±0.18 
CAG in A (mm):4.90±0.30*, B:3.93±0.25*, C:4.03±0.18* 
& D:2.96±0.18  
RBF in A (%): 52.65±0.04*, B:48.69±0.026*, C:48% ± 
0.029%* & D:9.14% ± 0.04% 
Mathur  et al. 
(85) 
CT 38, PID 
OFD+L-PRF 
OFD+ABG 
 
After 6 months** : 
PDR in  L-PRF vs. ABG:2.67± 1.29mm vs. 2.4± 1.06mm  
Mean CAG in  L-PRF vs. ABG: 2.53± 1.06mm vs. 2.67± 
1.63mm 
Shah  et al. (86)  SMD 40,PID 
OFD+L-PRF 
OFD+DFDBA 
 
After 6 months** : 
PDR in  L-PRF vs. DFDBA: 3.67± 1.48 mm vs. 3.70 ± 1.78 
mm   
CAG in  L-PRF vs. DFDBA: 2.97± 1.42 mm vs. 2.97 ± 
1.54 mm 
Rosamma  et al. 
(88) 
SMD 
45, horizontal 
defects 
L-PRF+OFD (A) 
L-PRF+ L-PRF 
membrane+ OFD (B) 
OFD (C) 
Clinical & 
radiographic 
After 9 months**: 
PDR in  A (mm):1.73±0.53*, B:1.7±0.45* & C: 1.1±0.38 
CAG in  A (mm):1.56±0.62*, B:1.7±0.52* & C:0.86±0.58   
Gupta  et al. (87) RCT 44, PID with CP 
L-PRF 
EMD 
Clinical & 
CBCT 
After 6 months**: 
PDR in  L-PRF vs. EMD: NS 
CAG in  L-PRF vs. EMD : NS 
Defect resolution in L-PRF: 32.41 ± 14.6% & EMD: 
43.07% ± 12.2* 
Bansal  et al. SMD 20, PID DFDBA+ Clinical & After 6 months**: 
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(77) L-PRF  
DFDBA 
radiographic PDR in  L-PRF (mm): 4.0±0.856* & control: 3.1±0.738 
CAG in  L-PRF (mm): 3.4±0.606* & control: 2.3±0.099 
Defect fill in  L-PRF (mm): 2.42±1.111 &  control: 
1.97±1.155 
Bajaj  et al. (89) RCCT 72, degree II MFI 
L-PRF+OFD 
PRP+OFD 
OFD 
Clinical & 
radiographic 
After 9 months** :  
PDR in  L-PRF (mm): 4.29±1.04* & PRP: 3.92±0.93* 
RVCAG (mm): in  L-PRF: 2.87± 0.85 * & PRP: 
2.71±1.04*  
RHCAG (mm): in  L-PRF: 2.75±0.94* & PRP: 2.5±0.83* 
RBF (%): in  L-PRF: 44.01±9.98*  & PRP: 42.83±11.15* 
Rosamma  et al. 
(10) 
CCT & 
SMD 
30, PID 
L-PRF+OFD 
OFD 
Clinical & 
radiographic 
After 1 year in test** :  
PDR: 2.27±0.29mm * 
CAG: 3.33±0.35mm* 
DDR:1.29±0.32mm * 
Pradeep  et al. 
(76) 
CT 90, PID with CP 
L-PRF+OFD 
PRP+OFD 
OFD 
Clinical & 
radiographic 
After 9 months: 
PDR (mm):  L-PRF (3.77 ± 1.19) & PRP (3.77 ± 1.07)  
CAG (mm):  L-PRF (3.17 ± 1.29) & PRP (2.93 ± 1.08) 
RBF (%):  L-PRF (55.41±11.39)* & PRP (56.85 ±14.01) * 
Lekovic  et al. 
(75) 
SMD 34, PID 
L-PRF+ BPBM 
L-PRF  (control) 
Clinical & 
radiographic 
After 6 months: 
PDR in test (mm): 4.47±0.78 on B & 4.29±0.82 on L sites 
* 
CAG in test (mm): 3.82±0.78 on B & 3.71±0.75 on L 
sites* 
RBF in test: 4.06±0.87 on B & 3.94±0.73 on L sites* 
Thorat  et al. 
(79) 
CCT 32, PID with CP 
L-PRF 
OFD 
Clinical & 
radiographic 
After 9 months: 
PDR in PRF vs. OFD (mm): 4.56 ± 0.37 vs. 3.56 ± 0.27 * 
CAG in  L-PRF vs. OFD (mm): 3.69 ± 0.44  vs. 2.13 ± 
0.43 * 
RBF in  L-PRF vs. OFD(%): 46.92 vs. 28.66* 
Sharma  et al. 
(78) 
RCCT 56, PID with CP 
L-PRF+OFD 
OFD 
Clinical & 
radiographic 
After 9 months: 
PDR in test vs. control (mm): 4.55 ± 1.87 vs. 3.21 ± 1.64 
CAG in test vs. control (mm): 3.31 ± 1.76 vs. 2.77 ± 1.44 
RBF in test vs. control: 48.26 ± 5.72* vs. 1.80 ±1.56 
Sharma  et al. 
(90) 
DBRS 36, degree II MFI 
L-PRF+OFD 
OFD 
Clinical & 
radiographic 
After 9 months**:  
PDR in test vs. control (mm): 4.056±0.416* vs. 
2.889±0.676  
RVCAG in test vs. control (mm): 2.333±0.485* vs. 
1.278±0.461,  
RHCAG in test vs. control (mm): 2.667±0.594* vs. 
1.889±0.758  
RBF in test vs. control (%): 50.8±6.24* vs. 16.7±6.42 
Chang  et al. 
(91) 
RS 6, PID L-PRF+BG 
Clinical & 
radiographic 
After 6 months: 
PDR (mm): 2.83 ± 1.70   
CAG (mm):  2.25 ± 1.76  
CT: Clinical trial, SMD: split mouth design, CCT: controlled clinical trial , RCCT: Randomized controlled clinical trial, RS: Retrospective 
study, DBRS: double-blind randomized study, PID: Periodontal intra bony defect, CP: chronic periodontitis MFI: Mandibular furcation 
involvement, CBCT: Cone beam computed tomography, OFD: Open flap debridement, L-PRF: Leukocyte- and platelet-rich fibrin, EMD: enamel 
matrix derivative, MF: Metformin, PD: Probing depth, PDR: Probing depth reduction, CAG: Clinical attachment gain, RVCAG: Relative vertical 
clinical attachment gain, RHCAG: Relative horizontal clinical attachment gain,  RBF: Radiographic bone fill, DR: Defect resolution, GML: 
gingival margin level, DDR: Defect depth reduction, RBD: Radiographic bone density, DFDBA: Demineralized freeze-dried bone allograft, NcHA: 
Nanocristaline hydroxyapatite, ABG: Autogenous bone graft, BPBM: Bovine porous bone mineral, BG: Bioactive glass *Statistically significant 
difference with control group, ** Statistically significant difference with base line evaluation, NS: Non significant 
Table 6. Case reports using L-PRF in advanced periodontal defects regeneration 
 Number of cases 
& Problem 
Used materials Evaluation methods Bone gain  
Shah et al. (93) 1, LCVG L-PRF Clinical  PD before surgery: mesial: 11mm, midbuccal: 8mm  
PD after surgery: mesial: 2mm, midbuccal: 1mm  
Anuroopa  et al. (94) 2,IBD L-PRF Clinical  After 6 months: 
PDR: 5mm (distal) & 6mm (mesial) for #12 & 3mm (distal) 
for #13 
CAG: 9mm for #12 & 5 mm for #13 
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Panda et al. (95) 1,IBD L-PRF+xenograft Clinical After 6 months: 
PDR: 5mm 
CAG: 6mm 
Desarda et al. (16) 2, GAgP L-PRF Clinical & 
radiographic 
Bone fill of 60-75% in case1 & 70-80% in case2 after 4 mo. 
radiographically 
After 9 mo. decreased PD & increased CA in both cases was 
observed.    
Table 7. Included clinical trials using L-PRF in endodontic surgery 
 
Type of 
study 
Number of cases, 
problem 
Used 
materials 
Evaluation 
methods 
Bone gain 
Dhiman et al (99) RCT 
30, Apico-
marginal lesions 
L-PRF 
Clinical and 
radiographic 
After 12 months**: 
PDR in L-PRF vs. control: 8± 0.92* 
vs. 7.27±0.96 
CAL in L-PRF vs. control: 7±0.92 
vs. 6.6±1.18 
SPLR in L-PRF vs. control: 
93.41±7.00 vs. 94.57±5.87 
Singh et al (15) CT 
15, peri-apical 
lesions 
L-PRF Radiographic CBR after 6 months 
RCT: Randomized clinical trial, CT: clinical trial, L-PRF: Leukocyte- and platelet-rich fibrin, PDR: Probing depth reduction, CAG: Clinical 
attachment gain, SPLR: Size of pri-apical lesion reduction, CBR: Complete bone regeneration, *Statistically significant difference with control 
group, ** Statistically significant difference with base line evaluation 
 
Table 8. Case reports using L-PRF for healing of peri-apical or endo-periodontal lesions 
 
No of 
cases 
problem Used materials 
Evaluation 
methods 
Bone gain 
Vidhale et 
al(2015)(112) 
3 RC 
L-PRF+ Iliac bone 
graft 
Radiographic 
After 3 months: Increased 
radiopacity as compared to 
earlier radiographs 
Nagaveni et al 
(2015)(102) 
1 
PID with EI 
(immature 
tooth) 
L-PRF 
Clinical & 
radiographic 
After 6 months: 
PDR: 2mm 
CBR 
Varughese et al 
(2015)(103) 
1 PID with EI 
L-PRF+ bone 
graft+ membrane 
Clinical & 
radiographic 
After 12 months: 
PDR: 4mm (distal) & 3mm 
(mesial) 
CBR 
Karunakar et al 
(2014)(104) 
2 PID with EI L-PRF 
Clinical & 
radiographic 
After 9 months: 
PDR: 6mm & 5mm 
CBR 
Panda et al 
(2014)(100) 
1 PID with EI PRF+ bone graft 
Clinical & 
radiographic 
After 6 months: PDR: 
6mm 
CAG: 7mm 
Goyal et al 
(2014)(22) 
1 EPL L-PRF+BG 
Clinical & 
radiographic 
PDR, CAG & RBF after 18 
months follow-ups 
Sam and 
Shivashankar 
(2014)(105) 
1 PID+EI L-PRF 
Clinical & 
radiographic 
After 6 months: 
Healthy gingiva and 
probing pocket depth of 3 
mm 
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Mazumdar et al 
(2013)(106) 
1 AL L-PRF Radiographic CBR after 1 year 
Shivashankar et al 
(2013)(107) 
2 AL L-PRF+HA Radiographic 
CBR after 2 year follow-
ups 
Patil et al 
(2013)(108) 
1 RC L-PRF+ DFDBA Radiographic 
Favorable bone 
regeneration after 6 
months 
Zhao et al 
(2012)(109) 
2 RC L-PRF+ BG 
Radiographic & 
CBCT scan 
satisfactory healing & bone 
regeneration after 4 mo. 
Bambal et al  
(2012)(110) 
2 RC L-PRF 3-D X-ray 
Test had better healing 
than the the other side. 
Jayalakshmi et al 
(2012)(111) 
1 
Anterior 
maxilla, RC 
L-PRF+ β-TCP 
Clinical & 
radiographic 
Faster bone healing in 1 
year follow-ups than 
literature 
Anilkumar et al 
(2009)(101) 
1 PID with EI PRF+ bone graft 
Clinical & 
radiographic 
Radiologic complete bone 
regeneration after 1year 
CR : Case report, EPL: Endo-perio lesion,  L-PRF: Leukocyte- and platelet-rich fibrin, PDR: Probing depth reduction, CAG: 
Clinical attachment gain, RBF: Radiographic bone fill, HA: Hydroxyapatite, PID: Periodontal intra bony defect, EI: Endodontic 
involvement, AL: Apical lesion, CBR: Complete bone regeneration, RC: Radicular cyst, DFDBA: demineralized freeze-dried bone 
allograft, CBCT scan: Cone- beam computed tomography scan, BG: Bioactive glass, β-TCP: tricalcium phosphate 
 
Table 9. Included studies on peri-implant bone defects treated by L-PRF 
 
Type of 
study 
Aim 
Number 
of cases 
Used 
materials 
Evaluation 
method 
Results 
Boora et al 
(2015)(114) 
RCT 
Pri-implant 
bone loss 
after insertion 
20 L-PRF 
Clinical & 
radiographic 
BL in L-PRF: 
After 1 month vs. base line**: mesial*: 
0.13±0.04 & distal*: 0.15±0.04 
After 3 months vs. base line**: mesial*: 
0.25±0.06 & distal*: 0.27±0.07 
After 3 months vs. 1 month**: mesial*: 
0.11±0.04 & distal*: 0.11±0.05 
Hamzacebi 
et al 
(2014)(113) 
RCT 
Pri-implant 
bone defect 
healing 
19 L-PRF Clinical 
After 6 months**: 
PDR in L-PRF* vs. control: 2.82 ± 1.03 mm 
vs. 2.05 ± 0.77 mm 
CAG in L-PRF* vs. control: 3.31 ± 1.08 
mm vs. 1.84 ± 0.81 mm 
Oncu et al 
(2014)(115) 
RCT 
Implant 
stability 
20 L-PRF Clinical 
ISQs of L-PRF vs. control:  After 1 week: 
69.3 ± 10.5 vs. 64.5 ± 12.2 
After 4 weeks: 77.1 ± 7.1 vs. 70.5 ± 7.7 
Mohamed 
et al 
(2012)(116) 
CR 
Retrograde 
peri-
implantitis 
healing 
1 
Xenograft+ 
L-PRF 
Clinical & 
radiographic 
After 1 year, health & function of the 
implant was restored 
Del Corso 
et al 
(2012)(117) 
CR 
Immediate 
implant 
insertion 
1 L-PRF 
Clinical & 
radiographic 
Restoration & esthetic results were stable 
after 2 years. 
RCT: Randomized clinical trial, CR1: Case report, L-PRF: Leukocyte- and platelet-rich fibrin, BL: Bone loss, PDR: Probing depth reduction, CAG: 
Clinical attachment gain, ISQs: implant stability quotients, * Significant difference compared to control, **Significant difference regarding 
understudy times 
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Table10. Included studies using L-PRF in treatment of bisphosphonate-related osteonecrosis of the jaw 
 
Type of 
study 
Number 
of cases 
Used materials 
Evaluation 
method 
Results 
Kim et al 
(2015)(119) 
CR 1 L-PRF+rhBMP2 Clinical After 11 weeks, total bone closure was observed. 
Kim et al 
(2014)(118) 
CS 34 L-PRF Clinical 26 complete and 6 delayed healing after 4 months 
Soydan et al 
(2014)(21) 
CR 1 
Double-layered 
PRF membrane 
Clinical 
Total bone closure after 1 month 
No gingival loss, inflammation, or infection after 
6 months 
CS: Case series, CR: Case report, rhBMP2: recombinant human bone morphogenetic protein-2 
 
Table 11. Case reports using L-PRF with the aim of bone regeneration 
 
Number of 
cases 
Problem Used materials 
Evaluation 
method 
Results 
Reddy et al 
(120) 
3 
Ridge 
augmentation 
L-PRF+DFDBA Clinical 
After 2 months: increased ridge 
dimensions 
Chaudhary 
et al (121) 
1 
Auto-
transplantation of 
an impacted incisor 
L-PRF+DFDBA 
Clinical & 
radiographic 
After 1 year: no complications 
Findik et al 
(20) 
3 Alveolar cleft L-PRF+ ASG Radiographic 
Initiating the orthodontic tooth 
movement in 3 to 4 months later. 
Graft in 1 case was exposed but 
recovered smoothly by hygiene 
recommendations 
L-PRF: Leukocyte- and platelet-rich fibrin, BRONJ: Bisphosphonate-related osteonecrosis of the jaw, DFDBA: demineralized freeze-dried bone 
allograft, ASG: Autogenous symphyseal graft 
 
 
and NBBM (22) did not increase bone healing significantly. For 
instance, Kim et al., demonstrated promising results by application 
of L-PRF mixed with TCP in sinus floor augmentation of rabbits 
(27); however, Yilmaz et al., showed that adding L-PRF to TCP 
had approximately equal NBF with sole use of TCP in pig tibial 
defects (37). Moreover, the highest NBF was shown in mixture of 
L-PRF with TA around dental implants inserted in the femur of 
dogs (78_8±6.95% and 87.5±9.15% after 4 and 8 weeks, 
respectively), which was significantly higher than empty defects, 
but not significantly more than TA and TA+PRP groups (35).  
Eight studies were conducted to evaluate L-PRF as the sole 
material. Two of them demonstrated its significant effect on 
calvarial defects in rabbits (21, 26), while three studies showed it 
did not significantly affect it (25, 33, 38). For example, Srisurang 
et al., showed positive effects of L-PRF on both hard and soft 
tissues in early phases of healing though NBF by L-PRF after 12 
weeks was not significantly higher than in controls (38). Also, the 
effectiveness of using L-PRF with titanium barriers was similar to 
using NBBM or BCP alone (25). However, Knapen et al., 
reported that L-PRF did not have additional effects on bone 
regeneration in calvarium defects of rabbits (12). Jeong et al., 
reported that use of L-PRF in sinus floor augmentation and 
immediate implantation was not a reproducible and predictable 
procedure (34). In order to evaluate osteogenic periosteal 
distraction, Pripatnanont et al., demonstrated that NBF was 
significantly greater when L-PRF was added when a modified 
Hyrax device was used in rabbits' mandible (30).  
Two studies evaluated other aspects of L-PRF (Table 1). Li et 
al., showed that NBF of lyophilized L-PRF, which has the 
improved storage capacity, was more than fresh PRF in critical-
sized bone defect (CSBD) of rats (18). Using titanium tubes to 
prepare L-PRF membrane led to bone regeneration after 15 days 
(24).  
Although rabbits used in 13 studies provides a suitable model 
to investigate regenerative potential  of bone substitute materials 
(128), according to Dohan Ehrenfest et al., human protocols 
which were performed on rabbits produced L-PRF-like material 
which was not actual L-PRF, and accurate results were not 
produced by rabbit studies (129). However, Tunali et al,. 
reported that rabbits could be used as a suitable model for 
titanium prepared PRF studies (24).   
According to the definition of CSBD (130), three studies 
investigated L-PRF in CSBD (18, 19, 21). Two of them showed 
significantly greater NBF in L-PRF groups after 6 weeks, and 
Honda et al., reported excellent healing of CSBD by combination 
of L-PRF with BMSCs. Since other sources of mesenchymal stem 
cells (MSCs) than bone marrow such as adipose tissues, dental 
tissues and induced pluripotent stem cells (iPSCs) (131-134), etc. 
have been introduced in recent years, evaluation of L-PRF and 
MSCs combination therapy may be considered in future studies.  
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Most studies evaluated the rate of NBF by HA analysis; 
nonetheless, some studies used radiologic assessments like CT 
(30, 36, 135) and micro CT (19, 30, 31, 33) alone or beside 
histological evaluations. Bone mineral density (BMD) 
measurement is one of the most important factors to assess bone 
quality (136). Recently, it is demonstrated that using both CT 
and micro CT scans are reliable for BMD measurements (137). 
Moreover, using CT scans has gained popularity in BMD 
measurements, and BMD derived from Hunsfield units has been 
highly reliable in the human jaws (138).     
Sole grafting of L-PRF  
According to the literature, platelet-derived epidermal growth 
factor (PD-EGF), platelet-derived growth factor A and B 
(PDGF), transforming growth factor beta1 (TGF-ß1), insulin 
like growth factor 1 and 2 (IGF), vascular endothelial growth 
factor (VEGF), endothelial cell growth factor (ECGF), and 
basic fibroblast growth factor (bFGF) are released from L-PRF 
even after seven days (7, 69), some of which play an important 
role in bone regeneration (139-141). Due to the 3-D structure 
of fibrin network and slow release of growth factors for at least 
7-10 days (7), use of sole L-PRF may cover two key factors of 
bone tissue engineering.  
In order to evaluate the effectiveness of using L-PRF as the 
sole material in bone defects, NBF of L-PRF groups in eight 
studies was significantly greater than empty defects after four 
weeks in dogs (33) or rabbits (25), six weeks in rats (18) and 
rabbits (21), eight weeks in rabbits (23, 26), and 12 weeks in 
pigs (37) or rabbits (25); moreover, it was not significantly 
greater than empty defects after ten and 20 days in sheeps (39), 
eight weeks in dogs (33), and 12 weeks in rats (19), rabbits (21) 
and guinea pigs (38). Consequently, although the rate of NBF 
with use of  L-PRF in some studies was significantly greater 
compared to empty defects 12 weeks or three months 
postoperatively, it was reported in other studies almost equal 
between two groups in this time.  However, L-PRF groups had 
insignificantly lower NBF than empty defects in two studies 
after 40 days in sheeps (39) and 12 weeks in rabbits (12).  
Comparison of sole application with mixtures of L-PRF, L-
PRF groups showed significantly lower NBF than L-PRF mixed 
with ABG after 8 weeks (23) and BCP after 10 , 20 and 40 days 
(39), but insignificant BMSCs (19), TCP (37) and ABG+DBB 
(23). However, NBF of L-PRF was more than mixing it with DBB 
(23) and NBBM (12) though it was not significant. Therefore, 
using mixtures of L-PRF may have better results than L-PRF as 
the sole graft especially with ABG or BCP, and further research is 
essential to identify the best mixture of L-PRF.    
When L-PRF was compared with PRP, the difference was 
not significant and even after four, six and eight weeks L-PRF 
showed  higher NBF, but after 12 weeks NBF by PRP was 
greater (21, 33). However, Hatakeyama et al., reported that 
platelet-poor plasma (PPP) had more NBF than both PRP and 
L-PRF groups after four and eight weeks (33). 
Using sole L-PRF had higher NBF than other bone grafts in 
four studies; to illustrate, it was higher than BCP after 10 and 
20 days (39) and three months (25), NBBM after one month 
(25) and 12 weeks (25), DBB after eight weeks (23), and using 
FGG alone after 12 weeks (38). However, the NBF by mixing 
ABG and DBB after eight weeks (23), BCP after 40 days (39), 
and TCP after 12 weeks (37) was greater than that of using sole 
L-PRF. This may indicate that using sole L-PRF can affect bone 
regeneration as well as various bone grafts. 
Two studies reported that the NBF of L-PRF was 
significantly increased in calvarial defects of rabbits among 
understudied times (12, 25). To illustrate, at 12 weeks, the NBF 
by both L-PRF and L-PRF mixed with NBBM was more than 
one and five weeks (12). Also, Ozdemir et al., reported that at 
three months after using L-PRF, NBF was greater than at one 
month (25).   
Mixtures of L-PRF 
When the effect of adding L-PRF to bone grafts were 
compared, L-PRF clots mixed with ABG after eight weeks (23) 
and six months (36),TCP after two, four, six and eight weeks 
(27)  BCP after ten, 20 and 40 days (39), four and eight weeks 
(31) and three months (32) and NBBM after one and two 
months (20) , and L-PRF membrane with NBBM after six 
months (9) showed significantly higher NBF than bone grafts 
alone; moreover, NBF of L-PRF clots mixed with NBBM after 
four and 12 weeks (12, 22), DBB and DBB with ABG after eight 
weeks (23), TA after four and eight weeks (35), and TCP after 
12 weeks (37) were more than bone grafts alone, but not 
significantly. However, mixtures of L-PRF with NBBM just 
after one and two weeks showed lower NBF  than NBBM group 
(22). Also, application of FGG with L-PRF was approximately 
equal to FGG groups (38).     
Mixing L-PRF with DBB, ABG and both of them after eight 
weeks (23), SFP after eight weeks around dental implants (28) 
and after 12 weeks in calvarium defects (29), TA after both four 
and eight weeks (35), TCP after 12 weeks (37), and BCP after 
ten, 20 and 40 days (39) revealed significant NBF compared to 
empty defects. However, NBF by L-PRF mixed with SFP after 
six weeks was not significantly greater compared to empty 
defects (29); furthermore, L-PRF mixed with NBBM showed 
lower NBF than empty non critical-sized calvarial defects after 
12 weeks (12). This result shows the effectiveness of adding L-
PRF to bone graft materials. 
Using L-PRF in humans  
The effect of L-PRF on Maxillary sinus floor augmentation 
and GBR techniques  
L-PRF membranes 
Three studies reported the use of L-PRF membranes in sinus 
floor augmentation (Table 2). Using it with NcHA embedded 
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in a highly porous silica gel matrix (NanoBone) (40), NBBM 
alone (49) or mixture of NBBM with ABG (8) indicated reletive 
efficiency of both NBF and RGM with resorbable collagen 
membrane groups (2). It is noticeable that survival rate of 
dental implants inserted in second surgery of these studies was 
100% after 12 weeks (40), 12 months (8) and 30 months follow-
ups (49). Also, effectiveness of L-PRF membranes was reported 
in GBR technique for both horizontal and vertical ridge 
augmentation used with allogenic cortical bone pins (53), ABG 
(61), ABG mixed with bovine hydroxyapatite (54) or ABG with 
using vertical alveolar distaction (62) with low level of evidence 
(Table 3). The choice of bone graft is one of the key factors in 
alveolar augmentation for GBR (142).  
Sole grafting of L-PRF  
Sole grafting of L-PRF was used in five studies. Simultaneous 
sinus lift, lateral window approach, and implantation using L-
PRF as the sole grafting material showed 100% survival rate of 
dental implants after six months (41, 46) and six years follow-
ups (43) (Table 2). In contrast to the results obtained in dogs 
(34), these studies indicated that L-PRF could be an adequate 
adjuvant to this technique and promote new bone regeneration 
around dental implants. 
Two studies reported 100% one-year survival rate of dental 
implants inserted immediately after either sinus floor 
augmentation for atrophic maxilla (residual bone hights: 3.7 
and 1.4 milimeter) by crestal aproach (52) or using both GBR 
and double J technique in atrophic ridges (55) with low level of 
evidence (Table 3). 
Moreover, OMSFE/PRF technique was presented in two 
studies in which survival rate of dental implants inserted 
immediately after sinus lift was 97.1% (n=35) after one year 
(47)and 97.8% (n=138) (44) (Table 2). Implant failures occurred in 
early phase; for example, according to Toffler et al., two implants 
failed four weeks after insertion because of infection. Perforation 
of sinus membrane and less than five milimeter residual subantral 
bone hight were also observed. Also, Peck et al., demonstrated 
successful use of OMSFE/PRF technique for immediate implant 
insertion in maxillary second premolar site with less than four mm 
residual vertical bone hight (Table 3) (59).  
Mixtures of L-PRF  
Histological and histomorphometric analyses of biopsies 
obtained after sinus floor augmentation during second surgery 
demonstrated that NBF of using L-PRF mixed with NBBM had 
no significant difference than using NBBM alone (11, 42). 
These results confirmed animal studies investigating mixtures 
of L-PRF and NBBM in calvarium defects of rabbits (12, 22). 
Moreover, dental implants (n=95) inserted immediately after 
sinus lift of severe atrophy of maxilla using a mixture of L-PRF 
and NBBM showed 100% survival rate at six to nine months 
after loading  (45). However, it was observed that five-year 
survival rate of dental implants (n=84) inserted with one-stage 
sinus lift using just bovine bone grafts was 100% (143).  
Choukroun et al., reported shorter healing period of L-PRF 
mixed with DFDBA after sinus lift (four months) than DFDBA 
alone (eight months) (48). In other words, addition of L-PRF to 
DFDBA may positively affect acceleration of healing process 
after sinus lift. 
The effect of L-PRF on socket preservation  
Sole grafting of L-PRF  
According to the results (Table 4), the positive effect of using  L-
PRF to preserve  both molar sites (66, 68-70, 72, 73), and 
nonmolar sites (64, 69) immediately after dental extraction was 
shown. However, Suttapreyasri et al., reported limited 
efectiveness of L-PRF for both bone formation enhancement and 
socket preservation in 20 premolar sites (65), in which there were 
no statistically significant differences in either width or hight 
reduction between using L-PRF and empty defects in the 
literature except for a study by Hauser et al., in which using L-
PRF showed significantly less width reduction than controls (64). 
In fact, the surgical prucedure may be as important as choosing 
the grafting material since using L-PRF with mucosal flap 
showed more width reduction vs. L-PRF alone. However, 
piezoelectric surgery with L-PRF use revealed sufficient and 
adequate socket filling, and it may be a safe technique to preserve 
the alveolar ridge (70). Furthermore, Peck et al., reported 
uneventful  use of L-PRF in a maxillary molar socket after 
removing a failed dental implant or extraction of a poor 
prognosis tooth, and successful new dental implant insertion was 
demonstrated three months or six weeks later, respectively 
(Table 4) (59, 71). 
Mixtures of L-PRF  
According to Barone et al., the mixture of L-PRF and CCPB used 
with collagen membrane in fresh extraction sockets in the 
maxillary esthetic zone which had partial or complete deficiency 
of the buccal bone plate showed significant vertical bone level 
improvement after five months. Also, delayed insertion of dental 
implants demonstrated favorable outcomes after one year 
follow-up (63). Gupta et al., evaluated mixture of L-PRF and 
BCP in a compromised extraction socket, and successful 
regeneration was gained after six months (Table 3) (67). 
The effect of L-PRF on periodontal intra-bony defects 
regeneration 
Sole grafting of L-PRF  
Comparison of the use of both L-PRF and conventional open 
flap debridement (OFD) with OFD alone according to the 
results showed better outcomes in the test groups (Table 5). To 
illustrate, in the treatment of mandibular grade II defects, 
significant differences in the parameters of PDR, CAG and RBF 
between tests and controls, and after 9 months to base line were 
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observed (89, 90). In the treatment of PID, in two split mouth 
design and randomized clinical studies, not only was probing 
depth reduced significantly but clinical attachment was also 
gained in the test than the control (10, 88, 92), but it was not 
significant in other clinical trials (76, 78, 82). Moreover, 
significant RBF and radiologic defect depth reduction was 
observed in the test groups compared to controls (10, 76, 78, 
92). However, the measured parameters improved significantly 
after nine months (82, 88, 92) and one year (10) compared to 
base-line, but it was not significant after nine months in two 
studies (76, 78). Thorat et al., evaluated the treatment of 
periodontal intra bony defects either with L-PRF or OFD alone, 
and presented significant improvement of the parameters in L-
PRF group though no significant difference was reported after 
nine months compared to base-line (79). Recently, Shah et al., 
conducted a meta-analysis showing mean standard difference 
of 2.33 (1.43, 3.23) for intra-bony defect reduction, 0.95 mm 
(0.20, 1.71) for CAG and 1.10 mm (0.56, 1.64) for PDR (126). 
Furthermore, adding 1% metformin to L-PRF revealed 
significant effects on PIDs (92). For future studies, it can be 
noticed that the parameters should be evaluated in various 
follow-ups like both nine months and one year in one study to 
better understand the effect of L-PRF on time for PID 
treatment.  
L-PRF has been used for treatment of a labial-cervical-
vertical groove, and displayed significant PDR (93). Moreover, 
L-PRF showed considerable RBF after four months, PDR and 
CAG after nine months in two generalized aggressive 
periodontitis patients (16) (Table 6).  
Mixtures of L-PRF  
In the treatment of PID (Table 5), two studies demonstrated that 
using L-PRF mixed with DFDBA significantly enhanced both 
PDR and CAG compared to DFDBA alone after six months (77) 
and one year(81). Furthermore, Lekovic et al., presented 
significant improvement of PDR, CAG and RBF regarding the 
use of L-PRF mixed with BPBM than L-PRF alone after six 
months(75). According to a retrospective study, the effectiveness 
of L-PRF mixed with bio-active glass was, also, demonstrated 
(91). However, although the outcomes of adding L-PRF to 
NcHA showed significant difference compared to base-line, both 
PDR and CAG was not significant between mixture of NcHA 
with L-PRF and NcHA after six months (83). Regarding split 
mouth design and randomized clinical studies, it was no 
significant difference between using L-PRF and each 
DFDBA(86), ABG(85) and EMD (87). Consequently, L-PRF 
may be an appropriate replacement for other grafts in PID 
regeneration.  
The effect of L-PRF on peri-apical and endo-periodontal 
defects treatment  
For regeneration of defects after root-end surgery, Singh et al., 
found compelete bone regeneration after six months of filling 
the defects with the sole L-PRF in 15 patients (96). Also, 
Dhiman et al., revealed significant effects of using sole L-PRF 
in the treatment of endo-periodontal lesions in a randomized 
clinical trial (97). Studies with low level of evidence, also, 
demonstrated satisfactory outcomes and bone regeneration 
after periapical defects treatment using L-PRF as either the sole 
material (100, 102-104, 108)or the mixture with iliac bone graft 
(110), bio-active glass (15, 107), hydroxyapatite (105), tri-
calcium phosphate (109) and DFDBA (106) after different 
follow-up times like four, 12, 18 or 24 months (Table 8).  Also, 
treatment of PID with endodontic involvement by using 
mixture of L-PRF and a bone graft was favorable after six 
months (98) and one year (99, 101).       
The effect of L-PRF on peri-implant bone  
Applying L-PRF around dental implants after insertion showed 
significantly less bone loss one and three months 
postoperatively (112). For peri-implant bone defects 
regeneration, significant PDR and CAG were revealed after six 
months using sole L-PRF (111). In other randomized clinical 
trial, stability of dental implants was investigated, and implant 
stability quotients (ISQs) for L-PRF group were reported more 
than control group after four weeks post-operatively though 
there was not a significant difference (113). Furthermore, a 
retrograde peri-implantitis was treated by using a xenograft 
and coverage by L-PRF (114). Also, two-year favorable results 
were observed after immediate insertion of a dental implant in 
post extraction site of a fractured maxillary central incisor with 
the labial gap between implant and residual buccal plate filled 
with mixture of L-PRF clots and CCPB, and covered with L-
PRF membrane. 
The effect of L-PRF on treatment of BRONJ 
Kim et al., reported a case series of the BRONJ treatment using 
L-PRF alone in a prospective study (116). They revealed 
promising results of using L-PRF in treatment of a large group 
of patients (n=32). There were no significant association 
between response to L-PRF and both low C-terminal 
crosslinked telopeptide of type I collagen (sCTX) concentration 
and presence of actinomycosis, the biomarkers for risk of 
BRONJ prediction.  Also, healing of bone exposures of BRONJ 
using double-layered L-PRF membrane after one month(14) 
and a mixture of L-PRF and rh-BMP2 after 11 weeks (117) was 
demonstrated in the literature. 
Other uses of L-PRF for bone regeneration  
Findik et al., reported successful reconstruction of unilateral 
alveolar cleft by using L-PRF and autologous symphyseal graft 
in young patients (13). Furthermore, Chaudhary et al., 
replanted an impacted central incisor in a prepared socket and 
splinted (119). L-PRF mixed with DFDBA placed in the defect 
and L-PRF membrane covered the defect from edge to edge. 
L-PRF in bone regeneration                                                                                                                                                                                                             63 
 
Regeneration, Reconstruction & Restoration 2016;1(2):47-68 
They observed no complication like root resorption or 
ankylosis after 1 year follow-up. Moreover, Reddy et al., 
demonstrated a novel technique of ridge augmentation in 
maxillary anterior region, and revealed a favorable use of a 
mixture of L-PRF with DFDBA with long palatal connective 
tissue rolled pedicle graft (118). 
Conclusion 
In conclusion, in animal studies, using the mixtures of L-PRF 
with ABG, NBBM and synthetic grafts has demonstrated 
significant bone regeneration; however, using L-PRF alone 
showed some challengeable results comparing to defects either 
grafted without L-PRF or left empty. Moreover, the rate of new 
bone formation was almost equal in both L-PRF and PRP 
groups with regard to the results of two animal studies. 
According to the human studies, L-PRF either solely or 
mixed demonstrated favorable results in sinus floor 
augmentation. With the aim of socket preservation, using L-
PRF solely showed non-significant results even though adding 
it to other grafts may have better effect on bone regeneration in 
dental socket. Using sole L-PRF in IBD revealed significant 
results when compared to OFD groups; also, it had similar 
effects on bone regeneration to use of other grafts without L-
PRF. Furthermore, using L-PRF showed appropriate outcomes 
in the treatment of peri-apical and endo-periodontal defects, 
peri-implant bone defects and BRONJ though further clinical 
studies are required for arriving at an evidence-based 
conclusion. 
Conflict of Interest: ‘None declared’. 
References 
1. Khojasteh A. Regenerative medicine in oral and maxillofacial 
surgery: is it a valuable modality? Int J Oral Maxillofac Surg. 
2013;42(10):1374-. 
2. Khojasteh A, Soheilifar S, Mohajerani H, Nowzari H. The 
effectiveness of barrier membranes on bone regeneration in 
localized bony defects: a systematic review. Int J Oral Maxillofac 
Implants. 2012;28(4):1076-89. 
3. Choukroun J, Adda F, Schoeffler C, Vervelle A. Une opportunité 
en paro-implantologie: le PRF. Implantodontie. 2001;42(55):e62. 
4. Behnia H, Khojasteh A, Kiani MT, Khoshzaban A, Mashhadi 
Abbas F, Bashtar M, et al. Bone regeneration with a combination 
of nanocrystalline hydroxyapatite silica gel, platelet-rich growth 
factor, and mesenchymal stem cells: a histologic study in rabbit 
calvaria. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 
2013;115(2):e7-e15. 
5. Khojasteh A, Eslaminejad MB, Nazarian H. Mesenchymal stem 
cells enhance bone regeneration in rat calvarial critical size defects 
more than platelete-rich plasma. Oral Surg Oral Med Oral Pathol 
Oral Radiol Endod. 2008;106(3):356-62. 
6. Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi 
J, et al. Platelet-rich fibrin (PRF): a second-generation platelet 
concentrate. Part I: technological concepts and evolution. Oral 
Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101(3):e37-
e44. 
7. Dohan Ehrenfest DM, de Peppo GM, Doglioli P, Sammartino G. 
Slow release of growth factors and thrombospondin-1 in 
Choukroun's platelet-rich fibrin (PRF): a gold standard to achieve 
for all surgical platelet concentrates technologies. Growth Factors. 
2009;27(1):63-9. 
8. Gassling V, Purcz N, Braesen JH, Will M, Gierloff M, Behrens E, et 
al. Comparison of two different absorbable membranes for the 
coverage of lateral osteotomy sites in maxillary sinus 
augmentation: a preliminary study. J Craniomaxillofac Surg. 
2013;41(1):76-82. 
9. Xuan F, Lee CU, Son JS, Jeong SM, Choi BH. A comparative study 
of the regenerative effect of sinus bone grafting with platelet-rich 
fibrin-mixed Bio-Oss(R) and commercial fibrin-mixed Bio-
Oss(R): an experimental study. J Craniomaxillofac Surg. 
2014;42(4):e47-50. 
10. Rosamma Joseph V, Raghunath A, Sharma N. Clinical 
effectiveness of autologous platelet rich fibrin in the management 
of infrabony periodontal defects. Singapore Dent J. 2012;33(1):5-
12. 
11. Tatullo M, Marrelli M, Cassetta M, Pacifici A, Stefanelli LV, 
Scacco S, et al. Platelet Rich Fibrin (P.R.F.) in reconstructive 
surgery of atrophied maxillary bones: clinical and histological 
evaluations. Int J Med Sci. 2012;9(10):872-80. 
12. Knapen M, Gheldof D, Drion P, Layrolle P, Rompen E, Lambert F. 
Effect of Leukocyte-and Platelet-Rich Fibrin (L-PRF) on Bone 
Regeneration: A Study in Rabbits. Clin Implant Dent Relat Res. 
2015;17(S1):e143-e52. 
13. Findik Y, Baykul T. Secondary closure of alveolar clefts with 
mandibular symphyseal bone grafts and with platelet-rich fibrin 
under local anesthesia: three case reports. J Contemp Dent Pract. 
2013;14(4):751-3. 
14. Soydan SS, Uckan S. Management of bisphosphonate-related 
osteonecrosis of the jaw with a platelet-rich fibrin membrane: 
technical report. J Oral Maxillofac Surg. 2014;72(2):322-6. 
15. Goyal L. Clinical effectiveness of combining platelet rich fibrin 
with alloplastic bone substitute for the management of combined 
endodontic periodontal lesion. Restor Dent Endod. 2014;39(1):51-
5. 
16. Desarda HM, Gurav AN, Gaikwad SP, Inamdar SP. Platelet rich 
fibrin: A new hope for regeneration in aggressive periodontitis 
patients: Report of two cases. Indian J Dent Res. 2013;24(5):627. 
64                                                                                                                                                                                                  Bastami & Khojasteh  
 
Regeneration, Reconstruction & Restoration 2016;1(2):47-68 
17. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, 
Ioannidis JP, et al. The PRISMA statement for reporting 
systematic reviews and meta-analyses of studies that evaluate 
health care interventions: explanation and elaboration. Ann Intern 
Med. 2009;151(4):W-65-W-94. 
18. Li Q, Reed DA, Min L, Gopinathan G, Li S, Dangaria SJ, et al. 
Lyophilized Platelet-Rich Fibrin (PRF) Promotes Craniofacial 
Bone Regeneration through Runx2. Int J Mol Sci. 2014;15(5):8509-
25. 
19. Honda H, Tamai N, Naka N, Yoshikawa H, Myoui A. Bone tissue 
engineering with bone marrow-derived stromal cells integrated 
with concentrated growth factor in Rattus norvegicus calvaria 
defect model. J Artif Organs. 2013;16(3):305-15. 
20. Oliveira M, Ferreira S, Avelino C, Garcia I, Mariano R. Influence 
of the association between platelet-rich fibrin and bovine bone on 
bone regeneration. A histomorphometric study in the calvaria of 
rats. Int J Oral Maxillofac Surg 2015;44(5):649-55. 
21. Kim T-H, Kim S-H, Sádor GK, Kim Y-D. Comparison of platelet-
rich plasma (PRP), platelet-rich fibrin (PRF), and concentrated 
growth factor (CGF) in rabbit-skull defect healing. Arch Oral Biol. 
2014;59(5):550-8. 
22. Yoon J-S, Lee S-H, Yoon H-J. The influence of platelet-rich fibrin 
on angiogenesis in guided bone regeneration using xenogenic 
bone substitutes: A study of rabbit cranial defects. J 
Craniomaxillofac Surg. 2014;42(7):1071-7. 
23. Pripatnanont P, Nuntanaranont T, Vongvatcharanon S, Phurisat 
K. The primacy of platelet-rich fibrin on bone regeneration of 
various grafts in rabbit's calvarial defects. J Craniomaxillofac Surg. 
2013;41(8):e191-e200. 
24. Tunalı M, Özdemir H, Küçükodacı Z, Akman S, Fıratlı E. In vivo 
evaluation of titanium-prepared platelet-rich fibrin (T-PRF): a 
new platelet concentrate. Br J Oral Maxillofac Surg. 
2013;51(5):438-43. 
25. Ozdemir H, Ezirganli S, Isa Kara M, Mihmanli A, Baris E. Effects 
of platelet rich fibrin alone used with rigid titanium barrier. Arch 
Oral Biol. 2013;58(5):537-44. 
26. Lee JW, Kim SG, Kim JY, Lee YC, Choi JY, Dragos R, et al. 
Restoration of a peri-implant defect by platelet-rich fibrin. Oral 
Surg Oral Med Oral Pathol Oral Radiol. 2012;113(4):459-63. 
27. Kim BJ, Kwon TK, Baek HS, Hwang DS, Kim CH, Chung IK, et al. 
A comparative study of the effectiveness of sinus bone grafting 
with recombinant human bone morphogenetic protein 2-coated 
tricalcium phosphate and platelet-rich fibrin-mixed tricalcium 
phosphate in rabbits. Oral Surg Oral Med Oral Pathol Oral Radiol. 
2012;113(5):583-92. 
28. Jang ES, Park JW, Kweon H, Lee KG, Kang SW, Baek DH, et al. 
Restoration of peri-implant defects in immediate implant 
installations by Choukroun platelet-rich fibrin and silk fibroin 
powder combination graft. Oral Surg Oral Med Oral Pathol Oral 
Radiol Endod. 2010;109(6):831-6. 
29. Lee EH, Kim JY, Kweon HY, Jo YY, Min SK, Park YW, et al. A 
combination graft of low-molecular-weight silk fibroin with 
Choukroun platelet-rich fibrin for rabbit calvarial defect. Oral 
Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(5):e33-8. 
30. Pripatnanont P, Balabid F, Pongpanich S, Vongvatcharanon S. 
Effect of osteogenic periosteal distraction by a modified Hyrax 
device with and without platelet-rich fibrin on bone formation in 
a rabbit model: A pilot study. Int J Oral Maxillofac Surg. 
2015;44(5):656-63. 
31. Acar AH, Yolcu Ü, Gül M, Keleş A, Erdem NF, Kahraman SA. 
Micro-computed tomography and histomorphometric analysis of 
the effects of platelet-rich fibrin on bone regeneration in the rabbit 
calvarium. Arch Oral Biol. 2015;60(4):606-14. 
32. Nacopoulos C, Dontas I, Lelovas P, Galanos A, Vesalas A-M, 
Raptou P, et al. Enhancement of Bone Regeneration With the 
Combination of Platelet-Rich Fibrin and Synthetic Graft. J 
Craniofac Surg. 2014;25(6):2164-8. 
33. Hatakeyama I, Marukawa E, Takahashi Y, Omura K. Effects of 
platelet-poor plasma, platelet-rich plasma, and platelet-rich fibrin 
on healing of extraction sockets with buccal dehiscence in dogs. 
Tissue Eng Part A. 2014;20(3-4):874-82. 
34. Jeong S-M, Lee C-U, Son J-S, Oh J-H, Fang Y, Choi B-H. 
Simultaneous sinus lift and implantation using platelet-rich fibrin 
as sole grafting material. J Craniomaxillofac Surg. 2014. 
35. Jeong K-I, Kim S-G, Oh J-S, Lee S-Y, Cho Y-S, Yang S-S, et al. 
Effect of platelet-rich plasma and platelet-rich fibrin on peri-
implant bone defects in dogs. J Biomed Nanotechnol. 
2013;9(3):535-7. 
36. Yuanzheng C, Yan G, Ting L, Yanjie F, Peng W, Nan B. 
Enhancement of the Repair of Dog Alveolar Cleft by an 
Autologous Iliac Bone, Bone Marrow–Derived Mesenchymal Stem 
Cell, and Platelet-Rich Fibrin Mixture. Plast Reconstr Surg. 
2015;135(5):1405-12. 
37. Yilmaz D, Dogan N, Ozkan A, Sencimen M, Ora BE, Mutlu I. 
Effect of platelet rich fibrin and beta tricalcium phosphate on bone 
healing. A histological study in pigs. Acta Cirurgica Brasileira. 
2014;29(1):59-65. 
38. Srisurang S, Kantheera B, Narit L, Prisana P. Socket preservation 
using platelet-rich fibrin in conjunction with epithelialized palatal 
free graft in minipigs. J Oral Maxillofac Surg Med Pathol. 
2014;26(2):108-17. 
39. Bölükbaşı N, Yeniyol S, Tekkesin MS, Altunatmaz K. The use of 
platelet-rich fibrin in combination with biphasic calcium 
phosphate in the treatment of bone defects: a histologic and 
histomorphometric study. Curr Ther Res Clin Exp. 2013;75:15-21. 
40. Bosshardt DD, Bornstein MM, Carrel JP, Buser D, Bernard JP. 
Maxillary sinus grafting with a synthetic, nanocrystalline 
hydroxyapatite-silica gel in humans: histologic and 
histomorphometric results. Int J Periodontics Restorative Dent. 
2014;34(2):259-67. 
L-PRF in bone regeneration                                                                                                                                                                                                             65 
 
Regeneration, Reconstruction & Restoration 2016;1(2):47-68 
41. Tajima N, Ohba S, Sawase T, Asahina I. Evaluation of sinus floor 
augmentation with simultaneous implant placement using 
platelet-rich fibrin as sole grafting material. Int J Oral Maxillofac 
Implants. 2013;28(1):77-83. 
42. Zhang Y, Tangl S, Huber CD, Lin Y, Qiu L, Rausch-Fan X. 
Effects of Choukroun's platelet-rich fibrin on bone regeneration 
in combination with deproteinized bovine bone mineral in 
maxillary sinus augmentation: a histological and 
histomorphometric study. J Craniomaxillofac Surg. 
2012;40(4):321-8. 
43. Simonpieri A, Choukroun J, Del Corso M, Sammartino G, 
Ehrenfest DMD. Simultaneous sinus-lift and implantation using 
microthreaded implants and leukocyte-and platelet-rich fibrin as 
sole grafting material: a six-year experience. Implant Dent. 
2011;20(1):2-12. 
44. Toffler M, Toscano N, Holtzclaw D. Osteotome-mediated sinus 
floor elevation using only platelet-rich fibrin: an early report on 
110 patients. Implant  Dent. 2010;19(5):447-56. 
45. Inchingolo F, Tatullo M, Marrelli M, Inchingolo AM, Scacco S, 
Inchingolo AD, et al. Trial with Platelet-Rich Fibrin and Bio-Oss 
used as grafting materials in the treatment of the severe maxillar 
bone atrophy: clinical and radiological evaluations. Eur Rev Med 
Pharmacol Sci. 2010;14(12):1075-84. 
46. Mazor Z, Horowitz RA, Del Corso M, Prasad HS, Rohrer MD, 
Dohan Ehrenfest DM. Sinus floor augmentation with 
simultaneous implant placement using Choukroun's platelet-
rich fibrin as the sole grafting material: a radiologic and 
histologic study at 6 months. J Periodontol. 2009;80(12):2056-64. 
47. Diss A, Dohan DM, Mouhyi J, Mahler P. Osteotome sinus floor 
elevation using Choukroun's platelet-rich fibrin as grafting 
material: a 1-year prospective pilot study with microthreaded 
implants. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 
2008;105(5):572-9. 
48. Choukroun J, Diss A, Simonpieri A, Girard M-O, Schoeffler C, 
Dohan SL, et al. Platelet-rich fibrin (PRF): a second-generation 
platelet concentrate. Part V: histologic evaluations of PRF effects 
on bone allograft maturation in sinus lift. Oral Surg Oral Med 
Oral Pathol Oral Radiol Endod. 2006;101(3):299-303. 
49. Bölükbaşı N, Ersanlı S, Keklikoğlu N, Başeğmez C, Özdemir T. 
Sinus augmentation with platelet-rich fibrin in combination 
with bovine bone graft versus bovine bone graft in combination 
with collagen membrane. J Oral Implantol. 2013. 
50. Tanaka H, Toyoshima T, Atsuta I, Ayukawa Y, Sasaki M, 
Matsushita Y, et al. Additional Effects of Platelet-Rich Fibrin on 
Bone Regeneration in Sinus Augmentation With Deproteinized 
Bovine Bone Mineral: Preliminary Results. Implant  Dent. 2015. 
51. Gassling V, Douglas TE, Purcz N, Schaubroeck D, Balcaen L, 
Bliznuk V, et al. Magnesium-enhanced enzymatically 
mineralized platelet-rich fibrin for bone regeneration 
applications. Biomed Mater. 2013;8(5):055001. 
52. Kanayama T, Sigetomi T, Sato H, Yokoi M. Crestal approach sinus 
floor elevation in atrophic posterior maxilla using only platelet 
rich fibrin as grafting material: A computed tomography 
evaluation of 2 cases. J Oral Maxillofac Surg Med Pathol. 2013. 
53. Toffler M. Guided bone regeneration (GBR) using cortical bone 
pins in combination with leukocyte- and platelet-rich fibrin (L-
PRF). Compend Contin Educ Dent. 2014;35(3):192-8. 
54. Montanari M, Callea M, Yavuz I, Maglione M. A new biological 
approach to guided bone and tissue regeneration. BMJ case 
reports. 2013;2013:bcr2012008240. 
55. Kim J-S, Jeong M-H, Jo J-H, Kim S-G, Oh J-S. Clinical application 
of platelet-rich fibrin by the application of the Double J technique 
during implant placement in alveolar bone defect areas: case 
reports. Implant Dent. 2013;22(3):244-9. 
56. Vijayalakshmi R, Rajmohan CS, Deepalakshmi D, Sivakami G. 
Use of platelet rich fibrin in a fenestration defect around an 
implant. J Indian Soc Periodontol. 2012;16(1):108-12. 
57. Kfir E, Kfir V, Eliav E, Kaluski E. Minimally invasive guided bone 
regeneration. J Oral Implantol. 2007;33(4):205-10. 
58. Angelo T, Marcel W, Andreas K, Izabela S. Biomechanical 
Stability of Dental Implants in Augmented Maxillary Sites: Results 
of a Randomized Clinical Study with Four Different Biomaterials 
and PRF and a Biological View on Guided Bone Regeneration. 
Biomed Res Int. 2015;2015. 
59. Peck MT, Marnewick J, Stephen LX, Singh A, Patel N, Majeed A. 
The use of leukocyte- and platelet-rich fibrin (L-PRF) to facilitate 
implant placement in bone-deficient sites: a report of two cases. 
SADJ. 2012;67(2):54-6, 8-9. 
60. Zhao J-H, Tsai C-H, Chang Y-C. Clinical application of platelet-
rich fibrin as the sole grafting material in maxillary sinus 
augmentation. J Formos Med Assoc. 2015. 
61. Gowda VS, Priya BM. An Innovative Combined Three 
Dimensional Augmentation of Alveolar Ridge using Titanium 
Mesh, PRF and Autogenous Bone Graft with Implant 
Placement. Chettinad Health City. 2013:137. 
62. Kocyigit ID, Tuz HH, Alp YE, Atil F, Tekin U, Coskunses FM. 
Correction of postsurgical alveolar ridge defect with vertical 
alveolar distraction of the onlay block graft. J Craniofac Surg. 
2012;23(5):1550-2. 
63. Barone A, Ricci M, Romanos GE, Tonelli P, Alfonsi F, Covani 
U. Buccal bone deficiency in fresh extraction sockets: a 
prospective single cohort study. Clin Oral Implants Res. 2014. 
64. Hauser F, Gaydarov N, Badoud I, Vazquez L, Bernard J-P, 
Ammann P. Clinical and histological evaluation of 
postextraction platelet-rich fibrin socket filling: a prospective 
randomized controlled study. Implant Dent. 2013;22(3):295-
303. 
65. Suttapreyasri S, Leepong N. Influence of Platelet-Rich Fibrin 
on Alveolar Ridge Preservation. J Craniofac Surg. 
2013;24(4):1088-94. 
66                                                                                                                                                                                                  Bastami & Khojasteh  
 
Regeneration, Reconstruction & Restoration 2016;1(2):47-68 
66. Girish Rao S, Bhat P, Nagesh KS, Rao GH, Mirle B, Kharbhari L, 
et al. Bone regeneration in extraction sockets with autologous 
platelet rich fibrin gel. J Maxillofac Oral Surg. 2013;12(1):11-6. 
67. Gupta HS, Chowdhary KY, Pathak TS, Kini VV, Pereira R, 
Mistry A. Socket Preservation at Molar Site using Platelet Rich 
Fibrin and Bioceramics for Implant Site Development. 
Development. 2013;3(2):102-7. 
68. Singh A, Kohli M, Gupta N. Platelet rich fibrin: a novel approach 
for osseous regeneration. J Maxillofac Oral Surg. 2012;11(4):430-
4. 
69. Simon BI, Gupta P, Tajbakhsh S. Quantitative evaluation of 
extraction socket healing following the use of autologous 
platelet-rich fibrin matrix in humans. Int J Periodontics 
Restorative Dent. 2011;31(3):285-95. 
70. Ruga E, Gallesio C, Boffano P. Platelet-rich fibrin and 
piezoelectric surgery: a safe technique for the prevention of 
periodontal complications in third molar surgery. J Craniofac 
Surg. 2011;22(5):1951-5. 
71. Peck MT, Marnewick J, Stephen L. Alveolar ridge preservation 
using leukocyte and platelet-rich fibrin: a report of a case. Case 
Rep Dent. 2011;2011:345048. 
72. Baslarli O, Tumer C, Ugur O, Vatankulu B. Evaluation of 
osteoblastic activity in extraction sockets treated with platelet-
rich fibrin. Med Oral Patol Oral Cir Bucal. 2015;20(1):e111. 
73. Kumar N, Prasad K, Ramanujam L, Ranganath K, Dexith J, 
Chauhan A. Evaluation of Treatment Outcome After Impacted 
Mandibular Third Molar Surgery With the Use of Autologous 
Platelet-Rich Fibrin: A Randomized Controlled Clinical Study. J 
Oral Maxillofac Surg. 2015;73(6):1042-9. 
74. Marrelli M, Tatullo M. Influence of PRF in the healing of bone 
and gingival tissues. Clinical and histological evaluations. Eur 
Rev Med Pharmacol Sci. 2013;17(14):1958-62. 
75. Lekovic V, Milinkovic I, Aleksic Z, Jankovic S, Stankovic P, 
Kenney EB, et al. Platelet-rich fibrin and bovine porous bone 
mineral vs. platelet-rich fibrin in the treatment of intrabony 
periodontal defects. J Periodontal Res. 2012;47(4):409-17. 
76. Pradeep AR, Rao NS, Agarwal E, Bajaj P, Kumari M, Naik SB. 
Comparative evaluation of autologous platelet-rich fibrin and 
platelet-rich plasma in the treatment of 3-wall intrabony defects 
in chronic periodontitis: a randomized controlled clinical trial. J 
Periodontol. 2012;83(12):1499-507. 
77. Bansal C, Bharti V. Evaluation of efficacy of autologous platelet-
rich fibrin with demineralized-freeze dried bone allograft in the 
treatment of periodontal intrabony defects. J Indian Soc 
Periodontol. 2013;17(3):361. 
78. Sharma A, Pradeep AR. Treatment of 3-wall intrabony defects in 
patients with chronic periodontitis with autologous platelet-rich 
fibrin: a randomized controlled clinical trial. J Periodontol. 
2011;82(12):1705-12. 
79. Thorat M, Pradeep AR, Pallavi B. Clinical effect of autologous 
platelet-rich fibrin in the treatment of intra-bony defects: a 
controlled clinical trial. J Clin Periodontol. 2011;38(10):925-32. 
80. Chang IC, Tsai CH, Chang YC. Platelet-rich fibrin modulates 
the expression of extracellular signal-regulated protein kinase 
and osteoprotegerin in human osteoblasts. J Biomed Mater Res 
A. 2010;95(1):327-32. 
81. Agarwal A, Gupta ND, Jain A. Platelet rich fibrin combined 
with decalcified freeze-dried bone allograft for the treatment of 
human intrabony periodontal defects: a randomized split 
mouth clinical trail. Acta Odontol Scand. 2016;74(1):36-43. 
82. Ajwani H, Shetty S, Gopalakrishnan D, Kathariya R, Kulloli A, 
Dolas R, et al. Comparative evaluation of platelet-rich fibrin 
biomaterial and open flap debridement in the treatment of two 
and three wall intrabony defects. J Int Oral Health. 
2015;7(4):32-7. 
83. Elgendy EA, Shady TEA. Clinical and radiographic evaluation 
of nanocrystalline hydroxyapatite with or without platelet-rich 
fibrin membrane in the treatment of periodontal intrabony 
defects. J Indian Soc Periodontol. 2015;19(1):61. 
84. Pradeep A, Nagpal K, Karvekar S, Patnaik K, Naik SB, 
Guruprasad C. Platelet Rich Fibrin with 1% Metformin for the 
Treatment of Intrabony Defects in Chronic Periodontitis: A 
Randomized Controlled Clinical Trial. J Periodontol. 
2015(0):1-14. 
85. Mathur A, Bains VK, Gupta V, Jhingran R, Singh G. 
Evaluation of intrabony defects treated with platelet-rich fibrin 
or autogenous bone graft: A comparative analysis. Eur J Dent. 
2015;9(1):100. 
86. Shah M, Patel J, Dave D, Shah S. Comparative evaluation of 
platelet-rich fibrin with demineralized freeze-dried bone 
allograft in periodontal infrabony defects: A randomized 
controlled clinical study. J Indian Soc Periodontol. 
2015;19(1):56. 
87. Gupta S, Jhingran R, Gupta V, Bains V, Madan R, Rizvi I. 
Efficacy of platelet-rich fibrin vs. enamel matrix derivative in the 
treatment of periodontal intrabony defects: a clinical and cone 
beam computed tomography study. J Int Acad Periodontol. 
2014;16(3):86-96. 
88. Rosamma Joseph V, Sam G, Amol NV. Clinical evaluation of 
autologous platelet rich fibrin in horizontal alveolar bony 
defects. J Clin Diagn Res. 2014;8(11):ZC43. 
89. Bajaj P, Pradeep A, Agarwal E, Rao NS, Naik SB, Priyanka N, et 
al. Comparative evaluation of autologous platelet‐rich fibrin and 
platelet‐rich plasma in the treatment of mandibular degree II 
furcation defects: a randomized controlled clinical trial. J 
Periodontal Res. 2013;48(5):573-81. 
90. Sharma A, Pradeep AR. Autologous platelet-rich fibrin in the 
treatment of mandibular degree II furcation defects: a 
randomized clinical trial. J Periodontol. 2011;82(10):1396-
403. 
L-PRF in bone regeneration                                                                                                                                                                                                             67 
 
Regeneration, Reconstruction & Restoration 2016;1(2):47-68 
91. Chang YC, Zhao JH. Effects of platelet‐rich fibrin on human 
periodontal ligament fibroblasts and application for periodontal 
infrabony defects. Aust Dent J. 2011;56(4):365-71. 
92. Pradeep A, Nagpal K, Karvekar S, Patnaik K, Naik SB, Guruprasad 
C. Platelet Rich Fibrin with 1% Metformin for the Treatment of 
Intrabony Defects in Chronic Periodontitis: A Randomized 
Controlled Clinical Trial. J Periodontol. 2015(0):1-14. 
93. Shah MP, Gujjari SK, Shah KM. Labial-cervical-vertical groove: A 
silent killer-Treatment of an intrabony defect due to it with 
platelet rich fibrin. J Indian Soc Periodontol. 2014;18(1):98. 
94. Anuroopa P, Padmavathi Patil VKR. Role and Efficacy of L-
PRFmatrix in the Regeneration of Periodontal Defect: a New 
Perspective. J Clin Diagn Res. 2014;8(12):ZD03. 
95. Panda S, Jayakumar N, Sankari M, Varghese SS, Kumar DS. 
Platelet rich fibrin and xenograft in treatment of intrabony defect. 
Contemp Clin Dent. 2014;5(4):550. 
96. Singh S, Singh A, Singh S, Singh R. Application of PRF in surgical 
management of periapical lesions. National J Maxial Surg. 
2013;4(1):94. 
97. Dhiman M, Kumar S, Duhan J, Sangwan P, Tewari S. Effect of 
Platelet-rich Fibrin on Healing of Apicomarginal Defects: A 
Randomized Controlled Trial. J Endod. 2015. 
98. Panda S, Ramamoorthi S, Jayakumar ND, Sankari M, Varghese SS. 
Platelet rich fibrin and alloplast in the treatment of intrabony 
defect. J Pharm Bioallied Sci. 2014;6(2):127-31. 
99. Anilkumar Kanakamedala GA, Sudhakar U, Vijayalakshmi R, 
Ramakrishnan T, Emmadi P. Treatment of a furcation defect with 
a combination of platelet-rich fibrin (PRF) and bone graft–a case 
report. ENDO (Lond Engl). 2009;3(2):127-35. 
100. Nagaveni N, Kumari K, Poornima P, Reddy V. Management of 
an endo-perio lesion in an immature tooth using autologous 
platelet-rich fibrin: a case report. J Indian Soc Pedod Prev Dent. 
2015;33(1):69. 
101. Varughese V, Mahendra J, Thomas AR, Ambalavanan N. 
Resection and Regeneration–A Novel Approach in Treating a 
Perio-endo Lesion. J Clin Diagn Res. 2015;9(3):ZD08. 
102. Karunakar P, Prasanna JS, Jayadev M, Shravani GS. Platelet-rich 
fibrin,“a faster healing aid” in the treatment of combined lesions: 
A report of two cases. J Indian Soc Periodontol. 2014;18(5):651. 
103. Sam G, Shivashankar VY. Management of a pathologically 
migrated upper anterior tooth using platelet-rich fibrin and a 
modified crown preparation technique. J Indian Soc Periodontol. 
2014;18(6):786. 
104. Mazumdar P, Nag D, Bhunia S. Treatment of Periapical Lesion 
with Platelet Rich Fibrin. Ind Med Gaz. 2013:28-33. 
105. Shivashankar VY, Johns DA, Vidyanath S, Sam G. Combination 
of platelet rich fibrin, hydroxyapatite and PRF membrane in the 
management of large inflammatory periapical lesion. J Conserv 
Dent. 2013;16(3):261-4. 
106. Patil VA, Desai MH, Patil VS, Reddy Kaveti H, Ganji KK, 
Danappanavar PM. A novel approach for treatment of an unusual 
presentation of radicular cysts using autologous periosteum and 
platelet-rich fibrin in combination with demineralized freeze-
dried bone allograft. Case Rep Dent. 2013;2013:893791. 
107. Zhao J-H, Tsai C-H, Chang Y-C. Management of radicular cysts 
using platelet-rich fibrin and bioactive glass: a report of two cases. 
J Formos Med Assoc. 2012. 
108. Bambal D, Manwar NU, Chandak M, Rudagi K. A comparative 
evaluation of the healing ability of bilateral periapical lesions 
treated with and without the use of platelet-rich fibrin. Todays 
FDA. 2012;24(6):54-7. 
109. Jayalakshmi KB, Agarwal S, Singh MP, Vishwanath BT, Krishna 
A, Agrawal R. Platelet-Rich Fibrin with beta-Tricalcium Phosphate-
A Noval Approach for Bone Augmentation in Chronic Periapical 
Lesion: A Case Report. Case Rep Dent. 2012;2012:902858. 
110. Vidhale G, Jain D, Jain S, Godhane AV, Pawar GR. Management 
of Radicular Cyst Using Platelet-Rich Fibrin & Iliac Bone Graft-A 
Case Report. J Clin Diagn Res. 2015;9(6):ZD34. 
111. Hamzacebi B, Oduncuoglu B, Alaaddinoglu EE. Treatment of 
Peri-implant Bone Defects with Platelet-Rich Fibrin. Int J 
Periodontics Restorative Dent. 2014;35(3):415-22. 
112. Boora P, Rathee M, Bhoria M. Effect of Platelet Rich Fibrin 
(PRF) on Peri-implant Soft Tissue and Crestal Bone in One-Stage 
Implant Placement: A Randomized Controlled Trial. J Clin Diagn 
Res. 2015;9(4):ZC18-21. 
113. Öncü E, Alaaddinoğlu EE. The effect of platelet-rich fibrin on 
implant stability. Int J Oral Maxillofac Implants. 2014;30(3):578-
82. 
114. Mohamed JB, Alam MN, Singh G, Chandrasekaran SC. The 
management of retrograde peri-implantitis: a case report. J Clin 
Diagn Res. 2012;6(9):1600-2. 
115. Del Corso M, Mazor Z, Rutkowski JL, Dohan Ehrenfest DM. 
The use of leukocyte- and platelet-rich fibrin during immediate 
postextractive implantation and loading for the esthetic 
replacement of a fractured maxillary central incisor. J Oral 
Implantol. 2012;38(2):181-7. 
116. Kim J-W, Kim S-J, Kim M-R. Leucocyte-rich and platelet-rich 
fibrin for the treatment of bisphosphonate-related osteonecrosis of 
the jaw: a prospective feasibility study. Br J Oral Maxillofac Surg. 
2014;52(9):854-9. 
117. Kim JW, Kim SJ, Kim MR. Simultaneous Application of Bone 
Morphogenetic Protein-2 and Platelet-Rich Fibrin for the 
Treatment of Bisphosphonate-Related Osteonecrosis of Jaw. J Oral 
Implant. 2016;42(2):205-8. 
118. Reddy PK, Bolla V, Koppolu P, Srujan P. Long palatal 
connective tissue rolled pedicle graft with demineralized freeze-
dried bone allograft plus platelet-rich fibrin combination: A novel 
technique for ridge augmentation-Three case reports. J Indian Soc 
Periodontol. 2015;19(2):227. 
68                                                                                                                                                                                                  Bastami & Khojasteh  
 
Regeneration, Reconstruction & Restoration 2016;1(2):47-68 
119. Chaudhary Z, Kumar YR, Mohanty S, Khetrapal A. 
Amalgamation of allogenic bone graft, platelet-rich fibrin gel, and 
PRF membrane in auto-transplantation of an impacted central 
incisor. Contemp Clin Dent. 2015;6(2):250. 
120. Shivashankar VY, Johns DA, Vidyanath S, Kumar MR. Platelet 
rich fibrin in the revitalization of tooth with necrotic pulp and 
open apex. J Conserv Dent. 2012;15(4):395. 
121. Ji B, Sheng L, Chen G, Guo S, Xie L, Yang B, et al. The 
Combination Use of Platelet-Rich Fibrin and Treated Dentin 
Matrix for Tooth Root Regeneration by Cell Homing. Tissue Eng 
Part A. 2015;21(1-2):26-34. 
122. Kulkarni MR, Thomas BS, Varghese JM, Bhat GS. Platelet-rich 
fibrin as an adjunct to palatal wound healing after harvesting a 
free gingival graft: A case series. J Indian Soc Periodontol. 
2014;18(3):399. 
123. Kazemi D, Fakhrjou A, Dizaji VM, Khanzadeh M. Effect of 
autologous platelet rich fibrin on the healing of experimental 
articular cartilage defects of the knee in an animal model. Biomed 
Res Int. 2014. 
124. Hiremath H, Kulkarni S, Sharma R, Hiremath V, Motiwala T. 
Use of Platelet‐rich fibrin as an autologous biologic rejuvenating 
media for avulsed teeth–an in vitro study. Dent Traumatol. 
2014;30(6):442-6. 
125. O'Connell SM, Impeduglia T, Hessler K, Wang XJ, Carroll RJ, 
Dardik H. Autologous platelet‐rich fibrin matrix as cell therapy in 
the healing of chronic lower‐extremity ulcers. Wound Repair 
Regen. 2008;16(6):749-56. 
126. Shah M, Deshpande N, Bharwani A, Nadig P, Doshi V, Dave 
D. Effectiveness of autologous platelet-rich fibrin in the 
treatment of intra-bony defects: A systematic review and meta-
analysis. J Indian Soc Periodontol. 2014;18(6):698. 
127. Ali S, Bakry SA, Abd-Elhakam H. Platelet rich fibrin in 
maxillary sinus augmentation: A systematic review. J Oral 
Implantol. 2015;41(6):746-53. 
128. Castaneda S, Largo R, Calvo E, Rodriguez-Salvanes F, Marcos 
M, Diaz-Curiel M, et al. Bone mineral measurements of 
subchondral and trabecular bone in healthy and osteoporotic 
rabbits. Skeletal Radiol. 2006;35(1):34-41. 
129. Dohan Ehrenfest DM, Lemo N, Jimbo R, Sammartino G. 
Selecting a relevant animal model for testing the in vivo effects 
of Choukroun's platelet-rich fibrin (PRF): rabbit tricks and traps. 
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 
2010;110(4):413-6; author reply 6-8. 
130. Bastami F. Letter to the Editor: Critical-sized bone defect in 
sheep model. Bone. 2014;68:162. 
131. Semyari H, Rajipour M, Bastami F, Semyari H. Isolation and 
Culture of Mesenchymal Stem Cells From Rabbit Scapular 
Subcutaneous Adipose Tissue and Their Ability to Differentiate 
Into Osteoblasts. Avicenna J Dent Res. 2015;7(2). 
132. Khojasteh A, Sadeghi N. Application of buccal fat pad-derived 
stem cells in combination with autogenous iliac bone graft in the 
treatment of maxillomandibular atrophy: a preliminary human 
study. Int J Oral Maxillofac Surg. 2016. 
133. Ishiy FA, Fanganiello RD, Griesi-Oliveira K, Suzuki AM, 
Kobayashi GS, Morales AG, et al. Improvement of In Vitro 
Osteogenic Potential through Differentiation of Induced 
Pluripotent Stem Cells from Human Exfoliated Dental Tissue 
towards Mesenchymal-Like Stem Cells. Stem Cells Int. 
2015;2015:249098. 
134. Kang R, Zhou Y, Tan S, Zhou G, Aagaard L, Xie L, et al. 
Mesenchymal stem cells derived from human induced pluripotent 
stem cells retain adequate osteogenicity and chondrogenicity but 
less adipogenicity. Stem Cell Res Ther. 2015;6(1):144. 
135. Jeong S-M, Lee C-U, Son J-S, Oh J-H, Fang Y, Choi B-H. 
Simultaneous sinus lift and implantation using platelet-rich fibrin as 
sole grafting material. J Craniomaxillofac Surg. 2014;42(6):990-4. 
136. Celenk C, Celenk P. Relationship of mandibular and cervical 
vertebral bone density using computed tomography. 
Dentomaxillofac Radiol. 2014. 
137. Parsa A, Ibrahim N, Hassan B, Stelt P, Wismeijer D. Bone 
quality evaluation at dental implant site using multislice CT, 
micro‐CT, and cone beam CT. Clin Oral Implants Res. 
2015;26(1):e1-e7. 
138. Shapurian T, Damoulis PD, Reiser GM, Griffin TJ, Rand WM. 
Quantitative evaluation of bone density using the Hounsfield 
index. Int J Med Sci. 2005;21(2):290-7. 
139. Houshmand B, Behnia H, Khoshzaban A, Morad G, Behrouzi G, 
Dashti SG, et al. Osteoblastic differentiation of human stem cells 
derived from bone marrow and periodontal ligament under the 
effect of enamel matrix derivative and transforming growth factor-
Beta. Int J Oral Maxillofac Implants. 2012;28(6):e440-50. 
140. Khojasteh A, Dashti SG, Dehghan MM, Behnia H, Abbasnia P, 
Morad G. The osteoregenerative effects of platelet‐derived growth 
factor BB cotransplanted with mesenchymal stem cells, loaded on 
freeze‐dried mineral bone block: A pilot study in dog mandible. J 
Biomed Mater Res B Appl Biomater. 2014. 
141. Khojasteh A, Behnia H, Naghdi N, Esmaeelinejad M, Alikhassy 
Z, Stevens M. Effects of different growth factors and carriers on 
bone regeneration: a systematic review. Oral Surg Oral Med Oral 
Pathol Oral Radiol Endod. 2013;116(6):e405-e23. 
142. Khojasteh A, Behnia H, Shayesteh YS, Morad G, Alikhasi M. 
Localized bone augmentation with cortical bone blocks tented 
over different particulate bone substitutes: a retrospective study. 
Int J Oral Maxillofac Implants. 2011;27(6):1481-93. 
143. Özkan Y, Akoglu B, Kulak-Özkan Y. Maxillary sinus floor 
augmentation using bovine bone grafts with simultaneous implant 
placement: a 5-year prospective follow-up study. Implant Dent. 
2011;20(6):455-9. 
 
Please cite this paper as: Bastami F, Khojasteh A. Use of 
Leukocyte- and Platelet-Rich Fibrin for Bone Regeneration: A 
Systematic Review. Regen Reconstr Restor. 2016; 1(2): 47-68. 
DOI: 10.7508/rrr.2016.02.001. 
 
